Hes not just a promising young offensive lineman with a cool hairdo! Like many of his Lions teammates, Peter Godber has taken an interesting path to the world of pro football. Along not only has Godber overcome some pretty heavy adversity on the injury front in order to work his way back to the top of the Lions depth chart, he also has plenty of big-game experience in college! Off the field, he enjoys spending time outdoors and learning about the human body. With that, we now present 5 Things To Know About Peter Godber.

RELATED: John White: 5 Things To KnowRELATED: Caleb Holley: 5 Things To KnowRELATED: Micah Johnson: 5 Things

As the Lions were on the clock with pick number three of the 2018 CFL Draft, Peter was at home in the Toronto area eagerly anticipating a call at some point near the top of that first round.

When his phone rang and Geroy Simons name popped up on the screen, he couldnt believe it. After all, Geroy was one of his favourite players growing up, especially after he got the chance to meet number 81 as a kid during some Grey Cup festivities in Toronto.

I still have the T-Shirt in my closet with his autograph on it. So it was kind of surreal for me to get a call from him, he said on draft night in 2018.

It truly is remarkable how things can come full circle in life.

Godber enjoyed a very successful career at Rice University, suiting up in 48 contests over four seasons with 35 starts. Along with playing both right and left guard, he helped the program to more than a few big victories over that span.

The 2013 Owls squad defeated Marshall to win Conference USA and then accepted an invitation to the Liberty Bowl where they fell to Mississipi State. The following year ended with a 30-6 win over Fresno State in the Hawaii Bowl where he and the big boys up front helped them churn out 600 yards of total offence. Godber proudly wears his rings from the Conference title and bowl game victory.

We mentioned he grew up in Toronto, so it comes as no surprise that the 63, 305-pound offensive lineman uses one of the best in the league as a template. Godber has always tried to model his game after long-time Toronto Argonauts and current Hamilton Tiger-Cats offensive tackle Chris Van Zeyl (pictured below).

Not a bad guy to look up to. A three-time CFL All-Star and two-time Grey Cup winner with the Argos, Van Zeyl also knows a thing or two about longevity as he has logged 173 career games in his first 11 seasons.

Photo: Johany Jutras

Which isnt surprising when you consider everything he accomplished to overcome his scary foot injury. Peter recently took an online course at Harvard on cognitive fitness that covered diet, exercise and sleep. Once his football days are over, he has thought about either opening a gym, becoming a personal trainer or getting his Masters Degree after studying kinesiology and sport management at Rice.

Peter also loves encouraging youngsters to be fit and active. Prior to the COVID-19 shutdown, he and Denver Broncos lineman Calvin Anderson- a former Rice teammate- were planning a football camp for kids.

And no, were not talking about Ric Flair. When he hasnt been working out with teammates at the facility, Peter has spent a lot of his social distancing time outdoors at some of the more scenic parks in the lower mainland. Along with taking in the sites, he really enjoys hiking.

Ive probably hit up every scenic park within 45 minutes of where I live, he said.

Matt Baker: mbaker@bclions.com

More here:
Peter Godber | 5 Things To Know About The Hulking Lineman - BC Lions

Broad new research has found proof that blood iron levels could play a crucial part in impacting how long you live. Usually, it is best to take longevity studies with a grain of salt, but the new paper is remarkable in its breadth, analyzing genetic information for more than one million people across three different public databases.

The study also focused on three main measures of aging: lifespan, healthspan, which are years lived free of disease, and longevity.

Throughout the research, ten key regions of the genome were proved to be related to these measures of long life, as well as gene sets associated with how the body metabolizes iron.

Simply put, having too much iron in the blood seemed to be connected to an increased risk of dying earlier.

We are very excited by these findings as they strongly suggest that high levels of iron in the blood reduce our healthy years of life, and keeping these levels in check could prevent age-related damage,says data analyst Paul Timmers, from the University of Edinburgh in the U.K. We speculate that our findings on iron metabolism might also start to explain why very high levels of iron-rich red meat in the diet has been linked to age-related conditions such as heart disease.

While correlation doesnt always mean causation, the scientists used a statistical technique known asMendelian randomizationto decrease bias and attempt to deduce causation in the data.

Micrograph of liver biopsy showing iron deposits due to haemosiderosis, the most important cause of iron overload. [Image: Wikipedia]As researchers detail, genetics are believed to have around a ten percent influence on lifespan and healthspan, and that can make it rather hard to pick out the genes involved from all the other aspects, such as smoking, eating, and drinking habits.

Five of the genetic markers the scientists found had not previously been considered significant at the genome-wide level. Some, such asAPOEandFOXO3, have been particularly discussed in the past as being important to the aging process and human health.

It is clear from the association of age-related diseases and the well-known aging loci APOE and FOXO3 that we are capturing the human aging process to some extent, the researchers write in theirpublished paper.

Besides genetics, blood iron is usually controlled by diet and has already been associated with a few age-related diseases, such asParkinsons, andliver disease. It also impacts our bodys capacity tofight off infectionas we get older.

This latest research can be added to the increasing evidence that iron overload or not being able to break it down properly, can have an impact on how long were likely to live, as well as the health status were likely to be in our later years.

Our ultimate aim is to discover how aging is regulated and find ways to increase health during aging,says Joris Deelen,who studies the biology of aging at the Max Planck Institute for Biology of Ageing in Germany. The ten regions of the genome we have discovered that are linked to lifespan, healthspan, and longevity are all exciting candidates for further studies.

The paper detailing the findings has been published inNature Communications.

Known for her passion for writing, Paula contributes to both Science and Health niches here at Dual Dove.

See the original post:
High Levels of Iron in the Body Leads to Decreased Healthspan and Lifespan - Dual Dove

This blog was written by Ashley Chin, BSc, a PhD candidate in the Division of Experimental Medicine at McGill University and Montreal Clinical Research Institute. Her research areas of interest include RNA and cell biology.

The answer lies in RNA. As we may know from the central dogma of molecular biology, RNA is best known as a messenger for DNA. Genetic information is passed on from DNA, to messenger RNA (mRNA), to protein. However, this dogma has led to an overly simplistic view. In the last few decades, scientists have dedicated themselves toward understanding the role that RNA molecules may play beyond being a simple genetic blueprint. They realize that having proper control over these microscopic regulators can translate into macroscopic health benefits in animals, including human. As such, the search for innovative RNA-based therapeutics have set sail.

An Emerging Drug for Mankind

For many years, RNAs have been deemed to be easily degraded and too cumbersome to be manipulated in the laboratory. Any scientists working with RNA would agree with this. This is because the human body is constantly releasing RNases into the environment, enzymes that are used for degrading RNA during normal cellular maintenance and for protecting us against harmful microorganisms. Although this benefit may initially seem like an advantage to you, it has in fact prevented scientists from using RNA as a potential therapeutic for many years, until some recent breakthroughs.

In recent years, RNAs are being explored as a new class of pharmaceutical target and drug, especially as vaccines for neurological disorders and infectious diseases (1-3). For example, to treat children with a crippling neurodegenerative disease called spinal muscular atrophy, building upon the initial RNA research conducted by Adrian Krainer and C. Frank Bennett, who were co-recipients of the 2019 Breakthrough Prize in Life Sciences, one pharmaceutical company and biotech teamed up to harness the power of antisense oligonucleotide therapy, a novel technique whereby carefully modified versions of DNAs are introduced into the cells (1-3). This is achieved by injecting the modified molecules into the fluid surround the spinal cord as a way to alter mRNA splicing, an editing process that is crucial for maintaining genetic information in the cells (1, 3). Additionally, last year, in a study conducted by Feldman and colleagues, they successfully produced effective mRNA vaccines against the influenza A viruses, the mastermind behind seasonal flu every winter. The researchers specifically targeted the H10N8 and H7N9 influenza strains that surfaced in 2013 by producing vaccines that contained chemically modified, full-length forms of those virus mRNAs. The vaccines were given in the deltoid muscle surrounding the shoulder during phase 1 of the clinical trial and yielded promising immune response from healthy participants (4).

What about the pandemic that is currently taking the world by storm paralyzing our daily routines, sinking the global economy and killing countless lives? In fact, much like the mRNA vaccine mentioned above, scientists are working at unprecedented pace to explore the feasibility of using mRNA vaccines to combat SARS-CoV-2, the coronavirus that is causing COVID-19 (5). This is because the traditional form of vaccines we are used to, which usually works by introducing a weakened or dead form of the virus to the body, requires a lengthy manufacturing time. Take the typical seasonal flu shots, an egg-based vaccine, as a more recent example, the virus needs to be first injected into a fertilized chickens eggs, where the selected virus strains incubate and replicate. Following, the viral containing fluids need to be harvested and deactivated before the purified virus antigen can be used in a vaccine (6). With the clock ticking and infection spreading as we speak, any mean to shorten vaccine manufacturing time is lifesaving.

RNA scientists believe mRNA vaccine can be a suitable solution in a time pressed pandemic as the mRNAs can serve as instruction molecules to direct a persons immune system to make their own protein reserve to combat a viral invasion. In this sense, the recipient uses the immune cells within its own body as a manufacturing hub for antibodies, rather than relying on external manufacturing capabilities, which is expected to save time when compared to traditional way of manufacturing vaccines.

In fact, albeit a development in progress, mRNA vaccines have other key advantages over traditional vaccines or DNA-based vaccine. The first and foremost is safety. mRNA is non-infectious, so it will not be integrated into the recipients genome and it can be digested by normal cellular processes. Through various chemical modifications, the longevity of these mRNAs in the body can be controlled. Additionally, the efficiency of mRNA delivery can be increased through designing and packaging the mRNA into protective, carrier molecules, which would enhance stability and encourage rapid uptake by the cells (7). Furthermore, mRNA vaccine can not only be a rapid alternative, but it is also scalable, as it relies on in vitro transcriptions, chemical reactions that are commonly practiced in laboratories, rather than relying on external factors such as the availability of hens eggs in addition to laboratory manipulation (6, 7).

As such, a large mRNA-based biotech is evaluating mRNA-1273 as a putative candidate vaccine for the novel coronavirus (5). The concept surrounding its vaccine is to inject a portion of mRNA that codes for the spike-like protein that is located on the surface of the virus, which allows it to bind to and invade human cells. In this fashion, the synthetic mRNA can travel throughout the bodies of their recipients, stimulating their immune systems to produce beneficial antibodies against the spike protein. Thus, when someone is exposed to the virus, the antibodies will be able to stop an infection by coating spike protein on the virus surface and preventing its capacity to attach to cells. Phase 1 clinical trial consisted of 8 healthy participants and yielded a positive outlook in terms of safety and efficacy. Phase 2, involving a few hundred healthy participants, is currently underway. If all goes well, phase 3 is scheduled to commence in the coming weeks (8).

Similarly, using mRNA-based technology, a pharmaceutical giant has teamed up with another biotech to develop a coronavirus vaccine (5). The most promising vaccine candidate is named mRNA-BNT162b1. This mRNA codes for a receptor binding domain antigen that is found on SARS-CoV-2, a portion of the protein that is required for the virus to bind to human cell. These companies have started phase 1/2 of their clinical trial, which consists of 45 healthy participants. Although some minor but not serious adverse effects were observed, the vaccine generated neutralizing antibodies that are predicted to prevent the coronavirus from operating. In fact, following two administrations of the low doses tested, the concentration of these antibodies were 1.8-2.8 times when compared to recovered patients (9). Nevertheless, whether higher concentration equates to immunity against the coronavirus remains to be tested (9, 10). Phase 2b/3 of the clinical trial is expected to start in few weeks (9).

At this point, due to the inherent complexity of our biological systems and the development of an effective vaccine, only time will tell whether we can effectively fight RNA with RNA. Afterall, this novel coronavirus is an RNA virus and it would be interesting to see if we can give it a taste of its own medicine by using synthetic mRNA molecule to create protein that our own immune systems can learn to combat. This is an exciting era for RNA researchers, as the world anxiously awaits its good news.

Although we have only discussed mRNA vaccines in the context of COVID-19, around the world, there are many other types of vaccine being explored in parallel. With the urgency of this matter, we certainly do not want to put all our eggs in one basket and concurrent vaccine development using a diversity of approaches are warranted.

Perspectives

We are only beginning to understand the many roles that RNAs play in our world. With the rapid technological advances, RNA-based therapies hold great promise for improving modern medicine within the foreseeable future, but much work remains to be done before it can establish itself as an efficient, scalable and go-to clinical solution. It may potentially serve as a great alternative or replacement for gene therapy against certain diseases. This is especially true since mRNA will not integrate into the host genome, minimizing the risk of unpredictable outcome associated with gene therapy.

References

1. Mercuri, E., et al. (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med, 378, 625-635.

2. Garde, D. (2018). Researchers behind Biogens breakthrough drug win big at Oscars of science. Statnews. https://www.statnews.com/2018/10/17/researchers-behind-biogens-breakthrough-drug-win-big-at-oscars-of-science/

3. Bennett, C., Krainer, A., & Cleveland, D.W. (2019). Antisense oligonucleotide therapies for neurodegenerative diseases. Annual Review of Neuroscience, 42, 385-406.

4. Feldman, R.A., et al. (2019). mRNA vaccines against H10N8 and N7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine, 37, 3326-3334.

5. Servick, K. (2020). Meet the company that has just begun testing a coronavirus vaccine in the United States. Sciencemag. https://www.sciencemag.org/news/2017/02/mysterious-2-billion-biotech-revealing-secrets-behind-its-new-drugs-and-vaccines

6. Yeung, J. (2020). The US keeps millions of chickens in secret farms to make flu vaccines. But their eggsw ont work for coronavirus. CNN Health. https://www.cnn.com/2020/03/27/health/chicken-egg-flu-vaccine-intl-hnk-scli/index.html

7. Pardi, N., et al. (2018). mRNA vaccines a new era in vaccinology. Nature Reviews, 17, 261-279.

8. Grady, D. (2020). Moderna coronavirus vaccine trial shows promising early results. The New York Times. https://www.nytimes.com/2020/05/18/health/coronavirus-vaccine-moderna.html

9. Pfizer and BioNTect. (2020). Pfizer and BioNTect announce early positive data from an ongoing phase study of mRNA-based vaccine candidate against SARS-COV-2. Pfizer News. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0

10. Herper, M. (2020). Covid-19 vaccine from Pfizer and BioNTect shows positive results. CNBC Newsletters. https://www.cnbc.com/2020/07/01/coronavirus-vaccine-from-pfizer-and-biontech-shows-positive-results-report-says.html

Read the original:
Messenger of DNA, Therapeutics and Coronavirus: How are they all linked? - PLoS Blogs

Antioxidants have generated quite the buzz in recent years as a category of substances known to delay cell damage. While research indicates that antioxidants can reduce inflammation, it's still unclear exactly how this correlates with overall health.

Plus, antioxidant supplements aren't necessary if you're eating a healthy diet, and can be dangerous in some cases. For example, too much beta-carotene the chemical that makes carrots and sweet potatoes orange can increase the risk of cancer if you smoke.

In this article, we discuss what researchers know so far about the role of antioxidants and how to get enough in your diet.

Antioxidants are substances found in plant foods, such as fruits, vegetables, pulses, coffee, and tea, along with supplements. They're essential to your health because antioxidants can prevent or delay cell damage caused by free radicals.

Free radicals are a normal byproduct of human life. For example, you produce them naturally in the form of lactic acid when you exercise. Free radicals can also come from outside sources like cigarette smoke, air pollution, certain medications, and sunlight.

The problem with free radicals is that they bind to cells in such a way that they damage the protein and DNA inside. However, that threat can be neutralized by antioxidants. That's why it's important to continually consume antioxidants in order to counter free radical damage in your body.

When you have too many free radicals running amok, it can cause cell damage particularly in cell membranes, fatty tissue, DNA, and proteins in the form of oxidative stress, which is associated with a number of diseases including:

However, just because antioxidants in the body can stave off oxidative stress doesn't mean that consuming antioxidants specifically can reduce your risk of disease.

There's no definitive answer to whether or not consuming antioxidants, either through food or supplements, reduces cancer risk or improves heart health, says Tim Spector, MD, FRCP, FRSB, a professor of genetic epidemiology at King's College London. And any product marketing that says otherwise is pushing a wellness agenda that's not backed by research.

Ultimately, the health benefits associated with antioxidants likely goes hand-in-hand with the benefits of eating a diet rich in whole foods and leading a healthy lifestyle.

Scientists do know that antioxidants can help reduce inflammation, a process by which white blood cells protect your body from outside invaders like bacteria and viruses. When cells are damaged by an overabundance of free radicals, an inflammatory response can occur.

Your body naturally produces some helpful antioxidants in the form of glutathione and alpha lipoic acid. But you can also get antioxidants from your diet. Fruits, vegetables, and coffee are all rich in antioxidants.

There are thought to be hundreds, if not thousands, of substances that act as antioxidants. Antioxidants include vitamins like vitamin C, vitamin E, and beta-carotene as well as minerals like selenium and manganese. They exist in many foods, from blueberries to dark chocolate.

A 2010 study, published in Nutrition Journal, looked at the antioxidant content of more than 3,100 foods, beverages, spices, herbs, and supplements, and found that a plant-based diet is best for protecting against oxidative stress. That's because plant-based foods have from 5 to 33 times more antioxidant content than meat products. According to the same study, some antioxidant-rich foods are:

Spector says it's important to note that there is no single, antioxidant-rich superfood out there. Therefore, eating the recommended five servings per day of fruits and vegetables is the best way to help ensure you're getting all the antioxidants you need.

You can also take antioxidant supplements, there is limited evidence supporting the benefits of consuming antioxidants in the form of supplements.

For example, a 2010 meta-analysis on antioxidant research, published in Research in Pharmaceutical Sciences, noted that multiple large scale randomized clinical trials found no reduced risk for cardiovascular events in people who took antioxidant supplements.

And for a 2011 review article in Oxidative Medicine and Cellular Longevity, researchers reporter that supplemental antioxidants may not offer the same sufficient protection as an antioxidant-rich diet from whole foods.

In fact, it can be difficult to disentangle the direct health benefits of antioxidants from the other nutrients in foods where they occur. Spector notes that antioxidants work best when consumed as whole foods in the form of vegetables, fruits, and legumes, for example.

Beyond diet, other healthy lifestyle choices like avoiding exposure to cigarette smoke and air pollutants, can reduce your risk of oxidative stress.

Here is the original post:
Why antioxidants are so important to your overall health - Insider - INSIDER

When it comes to the cast of The Good Place, each of the six main actors bought incredible talent to the hit NBC comedy. But, though they are all talented, Kristen Bell (Eleanor), DArcy Carden (Janet), William Jackson Harper (Chidi), Jameela Jamil (Tahani), and Manny Jacinto (Jason) all seem to be in awe of Ted Danson (Michael). Considered a veteran in the industry, Danson has a resume that would make plenty of actors envious.

Danson is the epitome of what it means to have a career with longevity. Prior to joining the cast of The Good Place, hed been working in film and television for over 40 years. At 72 years old, Danson shows no signs of stopping anytime soon and has a new role lined up which is set to premiere in 2021. But what is the secret to his success?

In an interview with Rolling Stone, the cast of The Good Place talked about what its like to work closely with Danson. They all spoke very highly of the Cheers alum and identified some key qualities that likely contribute to his success. Funnily enough, Dansons success might have a lot to do with simply being a good person. Naturally, his talent speaks for itself. But, (according to his castmates) Danson is also incredibly giving, supportive, respectful, and just downright fun.

RELATED: Jameela Jamil Calls Out Kim Kardashian Again and Fans Are Confused

In the interview, Carden gushed about how Danson always made her feel supported in scenes no matter what. In the 7th episode of the first season of The Good Place, Carden had to do Janets best approximation of human crying. As she was in front of a huge crowd of extras, she felt a bit uncomfortable and self-conscious about the situation. Sensing her discomfort, Danson decided to join Carden for a take to make her feel more at ease.

We turned to each other one take and grabbed each others hands, and did the cry up into the heavens together. It was so refreshing, his way of being like, I got your back. Im here with you. Ill go where you go. And from that moment on, you forget that he is the legendary Ted Danson. Youre just like, Oh, this is just the best scene partner I could possibly have. Hes just down for whatever. He loves to play. So whatever you give him, he will return it. Its incredible, Carden gushed about her fellow castmate of The Good Place.

Harper also echoed Cardens thoughts stating that Danson always helps to create an incredibly welcoming environment that is enjoyable for all. Theres a reason that people like him continue to work. Because you want to come to work and enjoy it. You want to come to work and like the people that youre with. And thats something that, he sets the tone in so many ways. Hes like, Im Ted fu*king Damson but were all going to be fu*king ladies and gentlemen here. And were going to treat each other with respect, and were going to laugh. Were going to make jokes, and were going to be kind, The Good Place alum stated about Danson.

Clearly, Dansons fellow castmates had nothing but nice things to say about him. Its great that he is able to help create such warm environments for his fellow actors. Perhaps thats what helped The Good Place cast give such compelling performances. We look forward to seeing what other projects Danson gets up to in the future.

More:
'The Good Place' Cast May Have Unlocked the Secret to Ted Danson's Success - Showbiz Cheat Sheet

Nowhere will you find more exciting ideas to invest in than life sciences, a broad topic that encompasses around 30 different branches of study, each of which could take a lifetime to fully comprehend. As investors, we dont want to rely on subject matter experts to understand what a company does. If we cant understand a companys business, we dont want to invest in it. We also want to avoid businesses with no traction. Drug development companies with no revenues that are burning through cash trying to bring a drug to market have volatile share prices for a reason. That volatility represents uncertainty. We prefer to stick with businesses that are already selling a product or service which is generating strong revenue growth consistently. These are businesses that are leveraging life sciences technologies to achieve above-average growth.

In writing about life sciences over the past seven years, weve come across dozens of interesting life sciences companies innovating across the globe such as:

Oftentimes well find groups of startups trying to solve similar problems like creating treatments using the human microbiome or trying to cure hearing loss. Technologies like mobile health, telemedicine, and medical chatbots are democratizing access to healthcare services. Big data is helping us better treat mental health conditions while telepsychiatry now democratizes access to mental health professionals. Were now able to create bionic limbs, bionic eyes, bionic ears, bionic pancreases, and artificial hearts. Soon, we might be harvesting organs from pigs to help solve the kidney transplant problem. Robots are now performing surgeries, and it wont be long until robots are doing dental work as well. Were building labs in the cloud and organs on chips. Optogenetics lets us control cells in living tissues with light. Deep learning algorithms now discover drugs which are then administered using smart pills, smart inhalers, or even wireless drug delivery chips. Patient data is now stored using electronic medical records, data which can then be analyzed by artificial intelligence algorithms to provide things like personalized cancer treatments. When a baby is born, were able to store stem cells from cord blood and then use them for stem cell transplants later on in life. These are only the startups we know about, because many life sciences startups choose to operate in stealth mode.

Some of the problems were trying to solve are themselves emerging, such as trying to kill super bugs that stem from antibiotic resistance, or developing vaccines for new viruses like the rona. (Johnson & Johnson is pouring millions into developing a coronavirus vaccine.) Many of the problems being worked on involve cures that havent been developed yet, something we looked at in our when will there be a cure series.

Examples of innovation in life sciences abound, so weve tried to narrow it all down to six areas of focus weve been researching for investment opportunities.

Lets start with genomics.

Perhaps no field in life sciences shows more promise than that of genomics. Using genetic sequencing machines, scientists are not only able to read the recipes of life, theyre also able to edit them using technologies like gene editing. Full genome sequencing has now fallen below the $1,000 mark, and some companies now have their sites set on a $50 genome sequencing price point.

Huge databases of DNA data are now being mined for insights, and scientists are even able to reconstruct composite images of criminals form crime scenes using DNA, something referred to as DNA phenotyping.

The field of genomics is exploding as prices plummet, speeds increase, and companies continue to find new use cases. Venture capitalists are pouring money into genomics startups across the globe with China and America being seen as the current leaders in genomics. In the future, well have a world where everyone is given personalized medicine tailored to their unique genetic makeup. This is why genetic testing is becoming so popular, something well cover extensively later in this piece.

You cant talk about genomics without mentioning Illumina, a company that all but dominates the market for machines that perform gene sequencing. Weve been longtime shareholders in Illumina and added to our position back in 2016 when shares dipped to around $135 a share. As the cost of gene sequencing plummets, even more use cases are opening up for Illuminas machines leaving them plenty of room for growth. One company trying to disrupt this plan is Chinas BGI Genomics which hopes to provide an alternative for Chinese companies that dont want to use Illumina or Oxford Nanopore sequencing machines. (Oxford Nanopore is a private company that builds smaller gene sequencing devices that are less accurate.) Another publicly traded company to watch in the sequencing space is 10X Genomics which is working on single cell sequencing.

Not all genomics stocks are leaders. There are plenty of laggards, like Bionano Genomics (BNGO) which had an IPO back in 2018. The company sells instruments meant to complement next-generation sequencing machines like those sold by Illumina. Unfortunately, they couldnt grow revenues in 2019 while losses continued to increase. You cannot be in a high-growth market and not have the revenue growth to show for it.

Human longevity also referred to as life extension science involves extending the human lifespan by rolling back the effects of aging. Technologies like machine learning and genetic sequencing now mean were better able to understand the aging process. Companies like Googles Calico are analyzing millions of anonymous DNA samples in an attempt to better understand the effects of genetics on aging.Were now able to develop cellular medicines that uses live cells to repair the body.

Other companies are trying to increase the human lifespan by lengthening ones telomeres or by minimizing oxidization which causes aging. Venture capitalists are pouring money into dozens of startups tackling the aging problem in areas like regenerative medicine or young blood transfusions.

From an investors perspective, human longevity presents both risks and potential rewards as living another 20 years can have some dire effects on some peoples retirement plans. Of the top longevity companies out there, some are publicly traded. Just be aware that some companies out there are selling snake oil. Theyre preying on older people who have money and the desire to live longer. Just because someone says theyre selling anti-aging pills doesnt mean they actually work.

Weve talked before about how The Internet of Things promises to connect everything to the cloud with the byproduct being loads of big data. The same holds true in the medical industry where connected medical devices allow doctors to monitor patients vital signs from afar. Breath diagnostics devices allow us to more quickly diagnose medical conditions. Ultrasounds can now be performed with smartphones, and ultrasound technology itself is finding many other uses cases like breaking up blood clots that cause strokes. Newly developed medical devices are used to administer electroceutical therapies and wearables are helping to treat mental health.

Perhaps some of the biggest advancements are being made in medical imaging where deep learning algorithms are used to interpret medical imagery. Dozens of startups are now developing medical imaging AI algorithms to do everything from measuring breast density to preparing surgeons for surgery.

The increasing sophistication of medical devices and medical imaging algorithms mean that doctors are more easily able to treat patients from afar. Companies like Teladoc (TDOC) make it possible for anyone with $40 to speak with a doctor. For retail investors looking to invest in the telemedicine trend, Teladoc is probably the only telehealth stock to own. There are also many startups working on telehealth using technologies like machine learning to improve upon their offerings.

As we continue to develop more connected medical devices and generate more medical images, the amount of big data to analyze in healthcare is growing exponentially. Many data analytics businesses are emerging which use this data for predictive analytics or to identify inefficiencies in processes. The ability to remotely monitor patients means were able to treat more people, more effectively.

A good example of remote patient care can be found in iRhythm Technologies (IRTC). Theyve built their entire business around a medical device for remote cardiac monitoring. It comes in the form of a wearable that can capture up to two weeks of ECG data while allowing the patient to conduct their life in a perfectly normal fashion. All that data is then fed to a deep learning model capable of arrhythmia detection at a level comparable to a panel of expert cardiologists for a total of 12 output classes.

Most patient data is now stored electronically instead of being stuffed in some filing cabinet. This means a patients data can be shared across healthcare providers allowing for better care. For retail investors, there are a number of publicly traded companies working on electronic health records (EHRs) which are rapidly becoming the norm. Practice Fusion even offers EHRs for free because they know the value is in the data. Companies like Health Catalyst (HCAT) then apply healthcare data analytics to all this big data to create large-scale efficiencies.

A brain-computer interface might be the Holy Grail for human advancement. Just imagine being able to increase your brain storage capacity exponentially. And its not just about augmenting the human brain. Being able to interface with the human brain means we no longer need to use keyboards or mice. Dozens of startups are working on neurotech applications like neuroprosthetics which can rectify brain damage or neuromodulation which can be used for pain management.

Our brains contain about 2.5 petabytes (2,500,000 gigabytes) of storage, enough to store the entire contents of all US academic research libraries.Stentrodes and neural dust are just some of the methods being used to access this incredible biological data storage mechanism. Biohackers can even do this at home using technologies like OpenBCI.

If youre not familiar with the drug discovery process, its largely inefficient with billions of dollars being spent developing drugs that never actually get approved following clinical testing.

Plenty of companies are working on removing all the inefficiencies from the process. For example, a handful of startups are working on helping patients find clinical trials worldwide which they can then participate in from home. Some of the biggest advancements being made in drug discovery are the many computational drug discovery startups popping up which use machine learning to optimize the discovery process.

When drugs do get approved, some create more problems than they solve. Look no further than Americas addiction to opiates which helps explain the proliferation of startups developing substance abuse apps. Many mental health problems stem from drug abuse, so sometimes cognitive behavioral therapies are a better option than hard drugs. Some of the more severe mental health conditions like schizophrenia still arent being treated effectively which means theres still lots more work to be done.

There is no cure for cancer, theres only early detection which could make most cancers benign. Thats just one example where advancements in medical testing could prove to save lives and money, something that everyone working in medicine wants to do. Unfortunately there have been some setbacks for investors, the most notable being the implosion of Theranos. Elizabeth Crazy Eyes Holmes was behind the blood testing company which was fawned over by just about everyone. Now, shes facing criminal charges while other companies try to fill the Theranos void with their own platforms for blood testing. Some of these come in the form of mobile diagnostics platforms that can be used at the point of care.

Advances in medical testing run the gamut, from AI algorithms that detect Alzheimers to blood tests that detect cancer. Were now able to use next-generation sequencing technologies to identify genomic sequences of pathogens that are present in a patients blood or even circulating tumor cells that indicate cancer. Were even working on building the tricorder from Star Trek.

Many companies are now able to detect the presence of cancer in biofluids like blood or urine. It isnt just about early detection, its also about monitoring the progress of cancer treatments. Traditionally, a doctor would take a piece of a tumor a biopsy in order to determine if it is cancerous or benign. Now, many startups are developing liquid biopsies or blood tests that are capable of detecting cancer. One publicly traded in this space is Guardant Health (GH), an $8 billion precision oncology company that primarily sells cancer blood tests.

Once a type of cancer has been identified, we can then use next-generation sequencing to identify cancer-associated alterations thatcan be attacked usingtargeted therapies.Foundation Medicine is a leader in this space with one of the worlds largest cancer genomic databases, holding more than 400,000 genomic profiles. The company had an IPO back in 2013 and got into bed with Roche a few years later. They were finally acquired by Roche in 2018.

Across the pond we have a few publicly traded companies in this space as well. Angle (AGL:LN), a $95 million company which continues to bleed cash while generating minuscule revenues, offers liquid biopsies. Oxford Immunotec (OXFD) is having a bit better luck on the revenue side of things with their blood test for tuberculosis.

Apocell used to be publicly traded but has since been taken private. Theres also a Japanese firm called Sysmex (6869:JP) which is the global market leader inhematology,occupying the number-oneshare of theworldwide market. They have a subsidiary called Sysmex Inostics which has developed an ultra-sensitivedigital PCR technologythat is capable of detecting cancer cell DNA directly from blood.

Blood isnt the only bodily byproduct used to detect cancer. A $13 billion company called Exact Sciences (EXAS) sells a stool DNA test for colorectal cancer. Exosome Diagnostics acquired by Bio-Techne is developing a urine test for prostate cancer. All these samples flying around mean that entire businesses are now being built around the storage and transportation of biological samples.

There are also companies developing cancer therapies that are fine-tuned to certain genomic profiles like personalized chemotherapy. This is where some genetics testing comes in handy.

To say that genetic testing has exploded is an understatement. There are now genetic tests for nearly everything, including genetics tests for pets. In looking at some of these testing use cases, they seem to be borderline gimmicks like DNA dating or genetic fitness tests. Others provoke a great deal of controversy, like genetic tests for intelligence. There are now DNA apps for nearly everything, but where it all started was with ancestry genetic tests.

Large ancestry testing companies like 23andMe and Ancestry.com quickly realized that the real value to be had was not in selling genetic tests, but collecting genetic data and monetizing it. This quickly led to privacy concerns around genetic data. As more and more companies started offering genetic testing services, the big providers started to pivot into genetic healthcare tests for hereditary diseases like cancer or heart disease. Soon, this started to attract the attention of regulatory authorities. Telling someone their dad isnt their dad isnt nearly as painful as mistakenly getting a double mastectomy because a genetic test said you were at risk for breast cancer. Youd be surprised to see how many ancestral differences you get when you run the same DNA sample through multiple test providers. (This is why Family Tree DNA offers a central DNA results database where you can upload all your test results.) When it comes to health related genetics testing, accuracy is paramount.

The evolution of genetics testing is now leading to new business models that try to adapt to the environment. Nebula now offers anonymous DNA testing. Centogene is building the worlds largest repository for genetic information on rare hereditary diseases in the world. Were learning more about how polygenic risk scores can help predict disease. Being able to interpret genetic data is becoming much easier thanks to technologies like machine learning. Even with all these new technologies, theres still an important human element to the whole thing. Finding out that youre at risk for hereditary cancer isnt all that useful unless someone tells you exactly what that means and what steps you should take if any.

For retail investors, theres one pure-play genetic testing stock you ought to consider which just expanded into personalized oncology with their acquisition of ArcherDX Invitae (NVTA). Since we first came across the company seven years ago, theyve come a long way.

Some other themes weve looked at manifest themselves over time as we notice their prevalence. For example, who knew that diabetes would be such a big industry.

All these people who talk about how big is beautiful need to realize that its just not. Sure, there are some cultures that glorify obesity because it represents wealth and security. In America, fat asses abound because people drive up to windows to consume two days of calories in one seating which they then wash down with a diet soda.

The hard truth is that obesity is unhealthy and a contributing factor to a huge global problem diabetes. Weve talked before about why there isnt a cure for diabetes yet. Until there is, we need to treat the more than 100 million U.S. adults who are now living with diabetes or prediabetes.

All kinds of companies are working on diabetes treatments. Dance Biopharm (now Aerami Therapeutics) is working on an inhaled insulin product. Intarcia Therapeutics is working on a potential once-a-year diabetes treatment. But no matter how compelling these products sound, there will be failures, like Cellnovos attempt at developing insulin pumps. Kind of hard to compete with Medtronic (MDT), one of the worlds biggest medical device makers, which already has that sorted with a digital form of an artificial pancreas. (Full disclosure: were long-time shareholders in MDT for dividend growth reasons.)

Another theme we looked at for a bit was non invasive prenatal testing (NIPT) which is pretty much what it says on the tin. Its a test that makes sure your little bundle of joy doesnt pop out with two heads, or be afflicted by any malady that would interfere with the perfect life youve planned for it. Plenty of companies are dabbling in this space, like Ariosa Diagnostics which was acquired by Roche since we last looked at them. Other publicly traded stocks in this space include Natera (NTRA) and Premaitha Health (YGEN:LN) which now goes under the name Yourgene.

We stopped looking at NIPT because we believed the NIPT growth story might be ending. We also didnt find the topic to be that interesting frankly unless of course they come out with a NIPT for intelligence which wed probably invest in.

Stem cells are kind of like a foundation cell that various types of other cells get built on like muscle cells or brain cells. These are useful for applications like regenerating body parts or figuring out what makes cancer cells replicate. One company we looked at, Cellular Dynamics, was in the business of producing stem cells. Theyve since been acquired by Fujifilm Holdings. Another company we looked at was Fate Therapeutics (FATE) which uses renewable master induced pluripotent stem cell (iPSC) lines to produce cellular immunotherapies. We have no idea what that actually means, which is why were not investors in the company. We only like to invest in businesses we can easily understand.

Over the years of developing our life sciences topics, we encountered quite a few companies that we just didnt fully understand. Roivant Sciences was one of them. So were the nant companies coming from the brain of Dr. Soon Shiong, one of the worlds most successful biotech investors. Its very difficult to understand some of these businesses without having a medical background, and if you need eight years of training to understand what a company does, its probably too complex for retail investors. Weve given up on trying to figure out how Nanthealth will revolutionize the U.S. healthcare system, or what Nantkwest does, and instead stick to companies with business models anyone can understand. Another area of life sciences weve looked into before but decided not to follow is RNAi therapeutics.

Another area we looked at briefly was RNAi therapeutics and publicly-traded RNAi companies like Benitec, Dicerna Pharmaceuticals, or Moderna which has soared after going public due to their work on a coronavirus vaccine. To this day, we still dont feel like we sufficiently understand what many of these companies do which means were not able to properly explain them to our readers. Instead of spending hours trying to understand how microRNA relates to RNAi, were staying away from drug development companies entirely. Even if a company has the greatest drug development platform in the world, theres always a risk theyll fail given all the pitfalls of drug development we discussed earlier. The exception to that rule might be the drug development arm of Johnson & Johnson, a company we hold as part of our dividend growth investing strategy.

Fields like cancer immunotherapy, cancer stem cell research, or epigenetics may have loads of promise, but most of these investments are just too complex for your average Joe investor to understand without having an interpreter. Lets talk about some stocks that you dont need an interpreter to understand.

Given the breadth of technologies to be found under life sciences we often take fleeting looks at companies that are doing cool things without necessarily doing any deep-dives or follow ups. These one-offs are oftentimes stocks or planned IPOs we come across that we think our readers might find interesting.

One thing all these stocks have in common is that theyre traded on major exchanges unlike penny stocks which you should avoid like the plague.

We never skip a chance to warn investors about the dangers to be found when dabbling in penny stocks (also called over-the-counter (OTC) stocks). Here are just some of the OTC companies weve written about.

Investing in any these companies would have proved to be a total disaster. Of course there are always some exceptions, but why try to walk through landmines to find them? Do not speculate on penny stocks, no matter how compelling their story is.

Oftentimes well come across micro-cap stocks on foreign exchanges which well write about. More often than not, these companies will end up going nowhere fast. Kiwi company Adherium (ADR:AU) was supposed to bring us intelligent inhalers. While investors continue to wait, their share price continues to plummet. We warned investors that Canadian firm BioMark Diagnostics (BUX:CN) might not have what it takes to bring cancer blood tests to market, and the company still appears to be going nowhere fast. Londons Tissue Regenix (TRX:LN) was working on some exciting new skin scaffolds, but you would have lost -90% of your investment waiting for them to finally start achieving some traction. Even though revenues are picking up and losses are trending in the right direction, shares continue their long downward slide. Its best not to try and catch a falling knife.

Some readers may wonder why we havent touched on one of the most exciting technology there is synthetic biology. Thats because weve dedicated an entire page to synthetic biology, our Guide to Investing in Synthetic Biology. The same holds true for gene editing, something we covered in our Guide to Investing in Gene Editing Stocks. We happen to classify gene editing and synthetic biology under our nanotechnology category, so you may want to go read our Guide to Investing in Nanotechnology Stocks and Companies next. Because life sciences is such a broad category, youll find it peppered throughout all the twelve categories of disruptive technologies we cover here at Nanalyze. For example, machine learning algorithms are now helping us understand extremely complex things such as the human microbiome.

Sure, you can cure your STDs without going to a doctor, but developing something as simple as a universal flu vaccine is still out of reach. While plenty of progress is being made in life sciences, there are still plenty of diseases we cant cure and problems we cant solve. Its safe to say that investors will continue to reap rewards by investing in life sciences companies for decades to come.

Interested in hearing more about investing in life sciences companies and stocks?Sign up for our weekly newsletter. Well keep you up-to-date on life sciences investments and all the disruptive technologies out there that ought to be on investors radar. No politics, no B.S., no corporate buzzword bingo.Click here to sign up for Nanalyze Weekly.

Link:
Investing in Life Sciences Stocks and Companies - Nanalyze

Kevin Special K Daley played with the Harlem Globetrotters, and was the body double for a young Michael Jordan in a 2002 Gatorade commercial; Alan Special K Kulwicki was the NASCAR 1986 Rookie of the Year; and pro tennis player Athanasios Special K Kokkinakis defeated No. 1-ranked Roger Federer in the second round of the 2018 Miami Open.

All special for sure, but theyve got nothing on how special vitamin K is when it comes to protecting your longevity. New research out of Tufts Universitys USDA Human Nutrition Research Center on Aging found that older adults with low vitamin K levels (below 0.5 nanomoles per liter) had a 19% higher risk of all-cause death over 13 years when compared with those who had adequate blood levels (more than 1.0 nmol/L).

Whats so special about vitamin K? It is essential for bone and blood vessel health and blood clotting. To make sure you have enough K-power, women 19 and older should consume 90 micrograms daily, men 120. Food sources supply plenty: Half a cup of blueberries delivers 14 mcg; half a cup of edamame, 21 mcg; half a cup of broccoli, 110 mcg; a cup of raw spinach, 145 mcg; and a half a cup of frozen/boiled collards, 530 mcg!

You do make another form of K called K2 (aka menaquinone) in your gut, but little is known about how much is absorbed or what stimulates the production. K2 is also found in fermented foods like nato (fermented soybeans) and sauerkraut. As Dana Carveys Church Lady used to say, Now, isnt that special?

Mehmet Oz, M.D. is host of The Dr. Oz Show, and Mike Roizen, M.D. is Chief Wellness Officer and Chair of Wellness Institute at Cleveland Clinic. To live your healthiest, tune into The Dr. Oz Show or visit http://www.sharecare.com.

2020 Michael Roizen, M.D. and Mehmet Oz, M.D.

Distributed by King Features Syndicate, Inc.

More:
Drs. Oz and Roizen: Vitamin K kick-starts a younger, healthier old age - The Union Leader

Not such a long time ago, we lived in a world where people believed what companies and advertising agencies told them about a product or service. Individuals gathered around their television screens to receive a steady stream of information and listen intently to the truth delivered.

The change came with the evolution of technology; suddenly there were rivers of information flowing to these same people, in their same houses. They tried to keep up, taking in what the rivers had to tell them, but the quality was declining as the speed increased relentlessly. Soon enough, a tsunami of information flooded through peoples houses, bowling them over and disrupting their day-to-day living. Consumers have been living amidst this content flood for quite a few years now, and its fair to say they are fed-up, much smarter and more distrusting.

The modern world is in the midst of a communication renaissance. The old model of interruptive advertising does not work anymore.

Today, people are looking for guides. They are looking for products and services that will genuinely support them, that they can connect with, and not those that will interrupt, distract and solely exploit them for financial gain.

So, how do companies effectively and communicate key messages in the current climate?

Companies need to offer value by engaging people in a conversation that lets them know they understand what the customer is going through, what problem they are facing, that they empathise with them and are here to help. A secure emotional connection between companies and our customers should not be underestimated, especially at this time of uncertainty. It establishes trust, loyalty and longevity in the relationship.

Importantly, we need to stop talking about ourselves, how fast and efficient our services are and how many awards we have won. Most people are juggling and struggling with everything already on their plate, and we need to offer something genuinely helpful for people to listen.

To help us build trust, we can call upon a tool in our communication arsenal, both compelling and old in equal measure: story. Humans are story seeking creatures, and we are hard-wired for them. As much as 65 per cent of all human interactions take the form of social storytelling. Listening to stories activates the auditory cortex and left temporal cortex of our brain. We are receptive to stories, we learn from them, and when they exist, there is more potential for a more significant emotional connection. Fundamentally, it is a universal language we all respond to, and it can help us create clear and compelling communication.

Annette Simmons, the author of The Story Factor, says, People want faith, they want faith in you. It is possible by tapping into the story of our customer, understanding what they truly want, what problem they are encountering and offering our service as the trusted guide. Getting clear on our brands narrative creates clear, relevant messages that cut through the content chaos of today.

To be clear, this is not about writing a fanciful fantasy for our customers, but employing a basic story-framework (used by most script-writers) to guide us in creating compelling brand narratives. We are building a story for our brand. The story brand framework supports us in understanding our customers better and what motivates them. To foster authenticity and effectively communicate through our marketing channels: on our websites, through emails, sales letters, keynotes and more. We see successful brand stories displayed by some of the largest companies in the world, including Apples Think Different, Nikes Just Do It, North Faces Never Stop Exploring. It is fair to say that without a clear story today, people just wont listen.

Here are three principles of Donald Millers story branding framework to consider:

Firstly, we, as the company, need to adjust our perspective to see our customers as the hero of the story. What do they want? The story only begins when a hero knows what they want and set out to achieve that goal. What do your customers genuinely want and need from you right now? The clarity of this answer is essential to stay relevant and become genuinely helpful.

Secondly, we, as the company, need to position ourselves as the guide. Most stories have a guide that supports the hero along the journey. They understand the problem and offer them a plan, a tool or some wisdom to help them overcome it. By positioning our company as the guide, we can employ two crucial traits of empathy and authority. We make ourselves the trusted resource to help them overcome their challenge. Communication expert, Nancy Duarte affirms this by saying, position yourself as Yoda and your audience as Luke Skywalker. It is a small but powerful shift that honours the journey of the audience and positions us as a leader providing wisdom, products and services with our audience to survive. To clarify our role as guide, we ask the question, who or what is opposing the hero getting what they want? Simply, identify the problem you are helping to solve.

Finally, the company needs to understand the transformation to be supported. Stories transform the hero. What will the heros life look like after you have helped them overcome the challenge? Branding messages need to speak to this shift to let people know how we can help them transform from weak to strong, instability to security, chaos to simplicity. How will it make their life better?

A compelling story can aid companies to float on the river of this communication renaissance. Companies begin to take charge and steer the boat when they identify what their customer needs, address the overwhelming problem they are experiencing and offer them a lifeboat to help. Consumers are looking out for these invitations and messages to help them survive and thrive, ones that they can trust to guide them to safety.

Samantha Herbert will be speaking the upcoming FEAL National Conference on identifying common values and shared belief systems to build empathy and resilience via the art of story-branding.

To register for Resilience, How to survive and thrive in a time of disruption on Thursday 6th August 2020

Visitwww.feal.asn.au/virtual-feal-conference-2020/

Here is the original post:
The communication renaissance interrupting the old world - Investment Magazine

The strategy analysis on Global Mesenchymal Stem Cells Market gives insights of market size, trends, share, growth, development plans, Investment Plan, cost structure and drivers analysis. With precise data covering all key aspects of the existing market, this report offers existing data of leading manufacturers. The Mesenchymal Stem Cells Market report covers marketing channels and market positioning to potential growth strategies, providing in-depth analysis for new competitors or exists competitors in the Mesenchymal Stem Cells industry. The Report Gives Detail Analysis on Market concern Like Mesenchymal Stem Cells Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments. The report provides key statistics on the market status of the Mesenchymal Stem Cells manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of Mesenchymal Stem Cells Market covering all important parameters.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request Exclusive Sample PDF Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/720

Global Mesenchymal Stem Cells Market 2020-2026: Competitive Analysis

The Mesenchymal Stem Cells Market report designed to provide entry support, customer profile and M&As as well as go-to-market strategy support. We provide a detailed analysis of key players operating in the global Mesenchymal Stem Cells Market, including key players such asPluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Scope of Mesenchymal Stem Cells Market:

The Mesenchymal Stem Cells market was valued at XX Million US$ in 2020 and is projected to reach XX Million US$ by 2027, at a CAGR of XX% during the forecast period. In this study, 2020 has been considered as the base year and 2020 to 2027 as the forecast period to estimate the market size for Mesenchymal Stem Cells.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Mesenchymal Stem Cells Market which would mention How the Covid-19 is Affecting the Mesenchymal Stem Cells Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Mesenchymal Stem Cells Players to fight Covid-19 Impact.

The report also focuses on global major leading industry players of Global Mesenchymal Stem Cells Market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. With tables and figures helping analyze worldwide Global Mesenchymal Stem Cells Market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position. The report provides detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Mesenchymal Stem Cells market. The Mesenchymal Stem Cells Market Report analyzes opportunities in the overall Mesenchymal Stem Cells Market for stakeholders by identifying the high growth segments.

The scope of the report is limited to the application of the type, and distribution channel. The regions considered in the scope of the report include North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC). This report presents the worldwide Mesenchymal Stem Cells market size (value, production and consumption), splits the breakdown (data status 20152019 and forecast to 2024), by manufacturers, region, type and application.

The Global Mesenchymal Stem Cells Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Mesenchymal Stem Cells Market report.

The report comprehends precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Mesenchymal Stem Cells Market contenders and emerging new companies. The report uses SWOT analysis for the growth assessment of the outstanding Mesenchymal Stem Cells Market players. It also analyzes the most recent enhancements while estimating the expansion of the foremost Mesenchymal Stem Cells Market players. Additionally, the key product category and segments along with sub-segments of the global Mesenchymal Stem Cells Market are studied in the global Market research.

What Reports Provides

Full in-depth analysis of the parent market Important changes in market dynamics Segmentation details of the market Former, on-going, and projected market analysis in terms of volume and value Assessment of niche industry developments Market share analysis Key strategies of major players Emerging segments and regional markets Testimonials to companies in order to fortify their foothold in the market.

Further, in the research report, the following points are included along with an in-depth study of each point:

* Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered.* Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.* Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.* Other analyses Apart from the information, trade and distribution analysis for the Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Reasons to Buy:

* Obtain the most up to date information available on the Mesenchymal Stem Cells projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Mesenchymal Stem Cells data.* Develop business strategies with the help of specific insights about the planned and announced Mesenchymal Stem Cells projects globally.* Keep abreast of key new-build Mesenchymal Stem Cells projects globally.* Assess your competitors planned and Mesenchymal Stem Cells projects and capacities.

Additionally, the report is joined by a vital examination of the Mesenchymal Stem Cells marketplace considering progress, part commitments, and future market forecasts. Furthermore, it offers detailed data of vendors including the profile, specifications of a product, sales, applications, annual performance in the industry, investments, acquisitions and mergers, market size, revenue, market share, and more. The report also studies individual regional market size along with country-wise and region-wise market size during the forecast period. The report also understands the export and import, production, and consumption of every particular region holding the highest market share, market size, or CAGR.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

* Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Buy This Research Study Report For Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/720

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Continue reading here:
Mesenchymal Stem Cells Market to Offer Lucrative Growth Prospects for Manufacturers by 2026 - Daily Research Chronicles

Rancho Santa Margarita, Calif and Bedford, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Blue California, a science-based, innovative ingredient solution provider, has just filed for a patent on therapeutic uses of the ingredient Ergothioneine. This follows Blue Californias Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress. Specifically, it claims that Ergothioneine can mitigate oxidative stress triggering the inflammatory response in many chronic conditions associated with heart disease, diabetes and cancer. Also, in support of other oxidative conditions associated with oxidative stress including COVID-19 as well as other viral diseases.

Blue California has been at the forefront of research and development regarding Ergothioneine using our branded ingredient ErgoActive, stated Dr. Priscilla Samuel, chief science officer at Blue California, We have found through our research that Ergothioneine has tremendous potential to combat oxidative stress and health conditions associated with it.

Ergothioneine is a naturally occurring amino acid normally provided to the body from dietary sources such as mushrooms in which it is particularly rich. Humans produce a highly specific transport protein called OCTN1 for Ergothioneine, leading many to speculate about its importance to human health.1 It is a super antioxidant, and renowned scientist Dr. Bruce Ames has even proposed classifying it as a longevity vitamin.2

The possibilities for ErgoActive to be incorporated in an immune health supplement or in a functional food or beverage are immense, commented Katie Ferren, vice president of sales and marketing at Blue California. This opens up the door for support in some exciting health applications.

Blue California is one of the only companies in the United States that has received a no-objection from the FDA to its GRAS notification on Ergothioneine with their branded ingredient ErgoActive. The company exclusively manufactures and distributes ErgoActive for Conagen, a greater Boston area biotechnology company with a large portfolio of products for the food, nutrition, and pharma markets. Vice President of Innovation at Conagen Dr. Casey Lippmeier explains, ErgoActive is an ideal nutrient and we produce it with a proprietary fermentation process. Ours is the only sustainable, commercially available source of Ergothioneine which does not rely on chemical synthesis or extraction from mushrooms.

Blue California and Conagen are eager for next steps. Blue California recently invested in both in vitro and in vivo research of ErgoActive. We will be studying how Ergothioneine supplementation can support various health benefits, including immune health. We also look forward to clinical studies that further test and demonstrate these novel benefits included in our patent application, and in the emerging scientific literature, said Dr. Samuel.

ErgoActive is a registered trademark of Blue California, Inc.

References:

About Blue California and Conagen

Blue Californiaprovides innovative solutions to global partners in the development and manufacture of botanical extracts and other unique ingredients. With more than 20 years of innovation, our ingredients are used in commercial products and applications in the industries of nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. http://www.bluecal-ingredients.com

Conagen is making the impossible possible. Our scientists and engineers are bettering humankind and the world by employing advanced synthetic biology tools for the bioproduction of high-value ingredients for food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. http://www.conagen.com

###

See the original post:
Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19 -...

Fossil fuels and nuclear energy to electricity power approximately 90% of global energy consumption according to the British Petroleum Statistical Review of World Energy 2020. Energy consumption behemoths China and Japan have left behind heavily subsidized, chaotically intermittent wind turbine and solar panel farms to build hundreds of New-Age Coal-Fired Plants. Coal-fired power plants, which are reliable, energy-dense, abundant, scalable and affordable are being built at such a rapid clip that any global, western environmental gains are being negated over the unreliability of renewables. According to the International Energy Agencys (IEA) World Energy Outlook 2019:

While the importance of transitioning to a carbon-neutral world is recognized, society is still heavily dependent on fossil fuels. Economic growth and a rising global population means that renewable energy sources (primarily the wind and sun) cant keep up with worldwide energy demand.

Reliable energy and electricity are a top national security concern the same way a nuclear arsenal is for first, second, and third world nations. China and Japan are simply keeping up with each other economically, militarily, and diplomatically by building hundreds of coal-fired power plants. Coal delivers continuous electricity 24/7/365 for Asia and the world. Why wouldnt both countries build coal-fired plants, and use them? When global environmentalist, Bjorn Lomberg says: there are Global priorities bigger than climate change. Mr. Lomberg is correct.

Both Asian powerhouses, and the billions without electricity are going to use anything possible (coal, natural gas, oil, petroleum, nuclear, future technologies) to acquire energy and electricity. Does any rational, non-ideological person believe Asia led by China and India are going to de-carbonize by de-industrializing? Fossil fuels will also rule in Africa, which is expected to add more than a half a billion people (to its) urban population by 2040.

In context, China didnt add this many people during its population boom between 1990-2010. Industrial and residential electrification using fossil fuels and nuclear are what billions in Africa and Asia need. For renewables to grow as a major source of energy to electricity:

Remove (taxpayer) subsidies, mandates and other forms of energy favoritism by letting technologies advance or fail in markets based upon their own true merit or lack thereof.

Otherwise, billions will suffer from the get-off-fossil-fuels-and-nuclear movement, and the consequences of various policy regimes denying consumers choices to best satisfy their energy usage requirement. Besides trying to ban fossil fuels and nuclear the De-carbonization movement is killing electrical generation for non-advanced countries, and continents. The costs are over $10 trillion annually.

Advanced countries such as China, India, Japan, and the U.S. use fossil fuels, because over 6,000 everyday products come from the derivatives of petroleum. Fossil fuels are also known energy-dense quantities. Energy density is defined as:

The energy stored per pound (and) is the critical metric for vehicles and, especially, aircraft, cruise ships and merchant ships. The maximum potential energy contained in oil molecules is about 1,500% greater, pound for pound, than the maximum in lithium chemistry. Thats why (all) aircraft, cruise ships and merchant ships, and rockets are powered by hydrocarbons.

Fossil fuels, and nuclear generated electricity are known physical quantities. Their favorable thermodynamic properties are the reasons why growing, and advanced countries will continue choosing oil, petroleum, natural gas, coal, and nuclear. Human wishes and desire-fulfillment economically, and historically began when fossil fuels, and nuclear energy were incorporated into everyday life.

Nuclear energy was after the Second World War; and is the only zero-carbon energy to electrical generation source. Both working together give certainty whereas renewables pose a real threat to conventional sources of electricity.

Since 1990 the global total primary energy supply has mainly been derived from fossil fuels. The approximately 7.7 billion living at this time want and need reliable, consistent sources of energy and electricity that fossil fuels provide even more so than nuclear generated energy to electricity.

If fossil fuels power and electrify the world, then the resurgence since the mid-2000s for American exploration and production (E&P) gains has changed the world in every conceivable way related to energy and electricity. The United States is expected sometime in the near future to become a net exporter of energy. An astonishing development when you consider during the President George W. Bush administration the U.S. imported most of its oil and natural gas for domestic use.

China, India, Africa, most of Central America, the Middle East, and large parts of Central Asia are struggling with little to no electricity. How can any western-led environmentalist or environmental organization believe all the above-mentioned nations, and continents wont follow the U.S. model for fossil fuel use?

Especially China, India, and Africa whose populations are growing the fastest plan for, allow, and legislate their economies, and national security reach new heights by hydraulic fracturing (fracking), or other methods of E&P for fossil fuels? The 2019 United States Energy Information Administrations International Energy Outlook factually reveals China, India, and Africa are using more fossil fuels and nuclear generated electricity to power their energy hungry economies than previously thought possible.

If a country, or continent does not have abundant, reliable, scalable, affordable, and flexible energy and electricity then you do not have an economy, or improved living standards. This is why hydrocarbons and nuclear are the moral answers for human longevity and prosperity decades ahead.

View original post here:
Fossil Fuels And Nuclear Power The World - OpEd - Eurasia Review

Your pension may gambling on highly-controversial life settlement funds which profit when people die ... [+] prematurely from COVID.

Whether you know it or not, your pension may be gambling on highly-speculative life settlement funds which profit when people die prematurely from COVID. Life settlement funds are controversial for a host of obvious and not-so-obvious reasons. These investments in a pension ensuring the retirement security of workers is doubly problematic.

Many public and private pensions are gambling on highly speculative funds that invest in so-called longevity-contingent assets, such as life insurance policies insuring the lives of individuals who are generally at least 70 years old. The insured individual must have a life expectancy ranging from, say, not less than two years to not more than 15 years. A given fund may have exposure to hundreds of lives in the portfolio with an average insured age of over 80 years old.

The sooner the terminally ill and other elderly insured individuals die, the betteras far as your pension is concerned.

With more than 80% of COVID deaths in the United States occurring in people aged 65 and older, this should be the best of times for gambling on these controversial funds which often promise annualized returns ranging from 8-12%. (Actual net returns are likely to be less than half those promised.)

If so, would it comfort you to know your pension was profiting from the misery of others?

Do you know whether your pension invests in life settlements? Have any such investments been clearly disclosed to you? Do the people managing your pension even know?

Believe it or not, they may not.

Today many alternative investment funds provide that they may withhold disclosure of underlying investments from pensions and participants, including stinky stuff like payday loans and life settlements.

Life settlement funds are controversial for a host of obvious and not-so-obvious reasons. Gambling on these highly speculative investments in a pension ensuring the retirement security of workers is doubly problematic.

Many regulators, lawmakers and other governmental authorities, as well as many insurance companies and insurance industry organizations, oppose the selling and buying of longevity-contingent assets. The industry and some of its participants have long been in legal and regulatory hot water. Opponents of the industry argue that these life insurance transactions are contrary to public policy by promoting financial speculation on human life and all-too-often involve elements of fraud and other wrongdoing.

Ask yourself: Why would an elderly, sickly or terminally ill insured person sell his or her life insurance policy? Because he or she needs cash to cover rising medical costs and living expenses? What are the chances the sale of that individuals life insurance policy may have been coerced or induced by fraud? Its no surprise that thoughtful regulators and lawmakers would be highly concerned.

The limited regulatory oversight of these funds is another major red flag. Many funds take the position that whole life settlements do not constitute securities under the federal securities laws and do not register as investment companies under the Investment Company Act of 1940. Compliance with other federal and state securities laws is also a concern. The SEC has long had difficulty reigning in industry abuses since unless securities are involved the agency generally lacks jurisdiction.

Worst of all, since the portfolio investments of these funds do not currently have a readily available market for valuation purposes, the likelihood that portfolio values, as well as investment returns may be inflated by the managers is high. This is particularly troublesome for open-ended investment funds, where new investors may be buying into a fund at an already inflated Net Asset Value (NAV). The life settlement asset class has had a troubled past with respect to inflated NAVs caused by funds underestimating life expectancies.

In other words, fund managers, are so hopeful that the old and sick insureds will die sooner rather than later, they assume the life expectancies will be shorter.

In Europe, a number of open-end funds (so-called sickened death bond funds) have gated, trapping investors. After waiting several years for the funds to liquidate, investors have recovered only pennies on the dollar.

In my opinion, additional regulatory action regarding overvaluations of the portfolios of these funds is almost certainly coming. If so, your pensionyour retirement securitymay be at risk.

In 2016, the Office of the Virgin Islands Inspector Generalissued a scathing report finding that the Virgin Islands General Employees Retirement System had entered into an extremely risky and questionable life settlement investment that jeopardized about $42 million of its investment portfolio. This was done without performing the necessary due diligence and obtaining the necessary expert advice, before exposing the pension fund to this high-risk investment. As a result, GERS has already written-off 20% or $8.4 million of the remaining value. In addition, GERS also granted a $10 million line of credit to the same partnership that is handling the viatical. The majority of the proceeds were to pay past due and near term premiums for the policies.

An advisor to the pension noted, There is uncertainty on the use of viaticals as an investment by a defined benefit plan. Also, The nature of the investment in viaticals, that is an investment seeking profits off death, raises issues of social responsibility.

To be sure, in my opinion, life settlement funds are the antithesis of socially responsible investing.

Should your retirement savings be in longevity-contingent assets supporting speculation on human life which often involve elements of fraud and other wrongdoing? First find out whether your pension is invested in these funds, then let your voice be heard.

Continued here:
Your Pension May Be Gambling On Human Life, Profiting From COVID Deaths - Forbes

While humans are all too familiar with the ravages of getting older, many trees seem to handle ageing a lot better.

Certain trees can live for thousands of years and appear to be immortal.

But not everyone is convinced these old timers can escape death due to old age.

Regardless, could humans with their relatively puny lifespans have something to learn from these ancient trees? Some scientists think so.

Establishing how old the oldest living tree is depends a bit on which plants are in the running for the title.

You could argue that Australia's Wollemi pine, which has been cloning itself for more than 60 million years, deserves the title. But that's kind of cheating because this involves multiple stems growing from the one rootstock.

This is why the oldest tree in the world is generally regarded as a single-stemmed bristlecone pine called Pinus longaeva.

This species can live to around 5,000 years and does well where most other plants cannot even grow in rocky, dry, high-altitude areas in the United States.

What's amazing is that scientists have not so far been able to show that getting older directly affects the health of such millennial trees, plant biologist Sergi Munne-Bosch from the University of Barcelona says.

It's because of this, some say these trees are essentially immortal.

But in a recent article, Professor Munne-Bosch argues that it's likely even ancient trees could die from old age assuming something else doesn't kill them first.

He emphasises that there's a difference between ageing, which is about how long an organism has lived, and age-related deterioration, which is referred to as senescence.

"Just because we can't track senescence in long-lived trees doesn't mean they are immortal."

Professor Munne-Bosch points to recent research on centuries-old Ginkgo biloba trees that found no evidence of senescence.

The study was the first to look for evidence of age-related changes in cells of the cambium, a layer just beneath the bark that contains cells that can produce new tissue throughout the plant's life.

It confirmed the long-lived trees, which in this case were up to 667 years old, were just as healthy as younger ones says Professor Munne-Bosch.

"They grow very well, they produce seeds, they produce flowers, so they are healthy."

He points out that even though a 667-year-old tree seems old when compared to a human, it is relatively young for a ginkgo.

"This species can live for more than two millennia."

Professor Munne-Bosch argues that the ginkgo researchers' data shows that older trees had thinner vascular tissue and that this hints at possible age-related deterioration that would be more obvious in even older trees.

Yet despite this deterioration, he says these trees are more likely to die from insects, disease, fire, drought or loggers, than old age.

"For a species that can live for millennia, aging is not really a problem in evolutionary terms because they are much more likely to die of something else."

The problem is there are so few of these long-lived trees that it's hard to get the data to know for certain whether they can die of old age.

"We cannot prove it either way," Professor Munne-Bosch says, adding that age-related deterioration is likely to happen in these trees at such a different pace compared to in humans.

"For a Ginkgo biloba, six centuries is not as physiologically relevant as it is to us."

Brenda Casper, a professor of biology at the University of Pennsylvania says it's not clear that the changes found in the older Ginkgo biloba trees were necessarily detrimental to the tree.

But she agrees the low number of millennial trees makes it hard to study their longevity.

"It's difficult to find statistical evidence for senescence."

Even if there were enough trees, she says some of the age-related deterioration may be hard to detect, or we may not know what to look for.

"It's not just internal physiology per se but it's the interaction of the tree with its environment."

For example, she says it would be hard to measure whether age had made a tree more susceptible to disease, or less structurally sound so it's more likely to fall over in a windstorm.

Even if the jury is out on whether millennial trees are immortal, some experts say their longevity could be inspirational for medical research.

Professor Munne-Bosch says such trees can draw on a bag of tricks to help them "postpone death".

First is having a simple body plan with modular-like branches and roots. This means they can compartmentalise any damaged or dead roots or branches and work around them.

"They can lose part of leaves or roots and continue to be healthy..

And he says although 95 per cent of the trunk of a tree might be dead, the living cambium just beneath the bark is "one of the secrets of longevity" in trees.

Millennial trees have used the combination of these features to their best advantage and Professor Munne-Bosch says these tricks are providing a model for scientists researching the negative effects of ageing.

"Imagine if we could regenerate our lungs or circulatory system every year, we would be much healthier than we are."

Want more science plus health, environment, tech and more? Subscribe to our channel.

Professor of biomedical engineering at the University of New South Wales, Melissa Knothe Tate is one researcher who is inspired by millennial trees.

"They have units and if one unit breaks you can replace it with another unit."

Only a small percentage of an individual long-lived tree may be alive, but she argues it's all about survival of the cells that are able to regenerate the tree.

"Those that survive best, survive longest."

"Millennial trees are the best survivors because they've seen a lot."

While a tree and a human might seem worlds apart, Professor Knothe Tate sees the similarities, pointing to the role of stem cells in maintaining bones in humans.

She says cells add new layers to bone, like tree rings, to increase girth and when bone is injured, stem cells quickly help repair it.

"We're constantly renewing our bones and trees do something similar."

Professor Knothe Tate says she is using stem cells and new biomaterials that emulate tree cambium, to create replacement tissue in the lab, and has several patents for the work.

"I think about plants a lot when I'm up in the mountains and amongst the trees."

Professor Knothe Tate, who draws on her training in philosophy, biology and mechanical engineering for her work, sees other similarities that can inspire research.

For example, she likens the human brain to the network of roots and branches that helps a tree remain resilient if one part is damaged, another part can sometimes take up the slack.

"As parts of the brain are injured or die, it's remarkable what functionality we can retain,

"If we knew which of the brain's networks were essential for certain functions, we may be able to grow them."

Want even more science, health and tech? Join the conversation on Facebook.

Professor Knothe Tate also set up a science education project for girls that explores the parallels between the biomechanics of trees and bones. It was inspired by her observation of how huge trees sway like a blade of grass in the wind.

She has high hopes for the potential of regenerative medicine research that draws on knowledge from other disciplines like plant biology.

"Then we can then start to think about making ourselves immortal."

Plant biologist Professor Munne-Bosch is also enthusiastic.

"The future of medicine is very similar to what has evolved in millennial trees."

But while regenerating tissues will help humans live much longer, he doubts we will ever be immortal.

"It won't be forever, because we are more likely to die of something else, whether it be an accident or a pandemic."

Get all the latest science stories from across the ABC.

Read more:
Are very long-lived trees immortal and what can they teach humans? - ABC News

Second-Quarter 2020 Results and Highlights:

Consolidated revenue decreased 14% to $87 million

Clinical Services revenue decreased 17% to $74 million

Pharma Services revenue increased 3% to $13 million

Pharma Services backlog increased 63% to $173 million

Financial position strengthened with $322 million net convertible note and equity offerings

Test menu expanded with suite of solid tumor liquid biopsy tests

Strategic collaboration and minority investment in Inivata established

High-capacity COVID-19 testing lab operationalized

FORT MYERS, FL / ACCESSWIRE / July 28, 2020 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2020.

"As expected, second quarter financial results were challenging due to the global COVID-19 crisis, which reduced both revenue and earnings," said Douglas M. VanOort, Chairman and CEO of NeoGenomics.

"Even in the midst of this pandemic, we made several strategic moves and invested in our business. We fortified our balance sheet with a successful offering of both common stock and convertible securities, we strategically invested in Inivata for access to liquid biopsy and minimal residual disease testing capabilities, we launched a suite of liquid biopsy tests, we moved forward with investments to further globalize our Pharma Services business, and we built and operationalized a high-capacity COVID-19 testing laboratory. We believe these investments will deliver both near-term and long-term growth, and that we exited the second quarter in a stronger competitive position for the future."

Second-Quarter Results

Consolidated revenue for the second quarter of 2020 was $87 million, a decrease of 14% over the same period in 2019. Clinical Services revenue decreased year-over-year by 17% to $74 million driven by a clinical test volume(1) decrease of 18%. Average revenue per clinical test ("revenue per test") remained stable at $351. Pharma Services revenue grew by 3% to $13 million compared to the second quarter of 2019, primarily due to the January 10, 2020 acquisition of the Oncology Division assets of Human Longevity, Inc. ("HLI - Oncology"). While disruptions in volume stemming from the COVID-19 pandemic reduced growth in both Divisions, there was steady improvement throughout the quarter.

Story continues

Gross profit was $28.0 million, a decline of 42.8%, compared to the second quarter of 2019. This reduction was the result of the combined effect of lower test volume due to the impact of the COVID-19 pandemic and our decision to retain employees.

Operating expenses increased by $2 million, or 5%, compared to the second quarter of 2019, reflecting investments in informatics, growth initiatives and costs associated with the integration of HLI - Oncology.

Net loss for the quarter was $7 million compared to net income of $2 million for the second quarter of 2019.

Adjusted EBITDA(2) was negative $7 million for the quarter compared to positive $15 million in the second quarter of 2019. Adjusted Net (Loss) Income(2) was a loss of $4 million compared to income of $7 million in the second quarter of 2019.

Cash and cash equivalents, including restricted cash, was $331 million and days sales outstanding ("DSO") was 92 days at the end of the second quarter of 2020 due to the impact of COVID-19 and the distribution of revenue.

(1) Clinical tests exclude requisitions, tests, revenue and costs for Pharma Services and COVID-19 Polymerase Chain Reaction ("PCR") tests.

(2) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled "Use of Non-GAAP Financial Measures." See also the tables reconciling such measures to their closest GAAP equivalent.

Conference Call

The Company has scheduled a webcast and conference call to discuss their first quarter results on Tuesday, July 28, 2020 at 8:30 AM EDT. Interested investors should dial (844) 602-0380 (domestic) and (862) 298-0970 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:30 AM EDT on August 11, 2020, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID Number is 35578. The webcast may be accessed under the Investor Relations section of our website at http://www.neogenomics.com. An archive of the webcast will be available until 08:30 AM EDT on October 28, 2020.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit http://www.neogenomics.com/

Forward Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2020. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company's practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent the Company's estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company's estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

For further information, please contact:

NeoGenomics, Inc.

William BonelloDirector, Investor Relations(239) 690-4238 (w)(239) 284-4314 (m)bill.bonello@neogenomics.com

NeoGenomics, Inc.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)

June 30, 2020 (Unaudited)

December 31, 2019

ASSETS

Cash and cash equivalents

$

295,281

$

173,016

Accounts receivable, net

87,766

94,242

Inventories

21,627

14,405

Other current assets

14,326

9,075

Total current assets

419,000

290,738

Property and equipment (net of accumulated depreciation of $80,143 and $68,809 respectively)

83,969

64,188

Operating lease right-of-use assets

47,554

26,492

Intangible assets, net

125,821

126,640

Goodwill

210,833

198,601

Restricted cash, non-current

36,030

-

Prepaid lease asset

6,084

-

Investment in non-consolidated affiliate

13,137

-

Other assets

3,057

2,847

TOTAL ASSETS

$

945,485

$

709,506

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and other current liabilities

$

52,746

$

50,091

Short-term portion of financing obligations

4,458

10,432

Short-term portion of operating leases

4,496

3,381

Total current liabilities

61,700

63,904

Long-term portion of financing obligations

1,911

See the original post:
NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic - Yahoo Finance

LOS ANGELES, United States: QY Research has recently published a report, titled Global Adrenomyeloneuropathy Treatment Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Adrenomyeloneuropathy Treatment market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Adrenomyeloneuropathy Treatment market include: Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1664172/global-adrenomyeloneuropathy-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Adrenomyeloneuropathy Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Adrenomyeloneuropathy Treatment Market Segment By Type:

Steroid Replacement TherapyStem Cell Transplant By the end users, this report covers the following segmentsHospitalsClinicsAmbulatory Surgical CentersOthers Competitive Landscape: The Adrenomyeloneuropathy Treatment key manufacturers in this market include:Ascend BiopharmaceuticalsNovadip BiosciencesEureka TherapeuticsHuman LongevityRegeneusAllogene TherapeuticsBioRestorative TherapiesImmatics BiotechnologiesNewLink GeneticsCytori TherapeuticsTalaris Therapeutics

Global Adrenomyeloneuropathy Treatment Market Segment By Application:

HospitalsClinicsAmbulatory Surgical CentersOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Adrenomyeloneuropathy Treatment market.

Key companies operating in the global Adrenomyeloneuropathy Treatment market include Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1664172/global-adrenomyeloneuropathy-treatment-market

TOC

1 Market Overview of Adrenomyeloneuropathy Treatment1.1 Adrenomyeloneuropathy Treatment Market Overview1.1.1 Adrenomyeloneuropathy Treatment Product Scope1.1.2 Market Status and Outlook1.2 Global Adrenomyeloneuropathy Treatment Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Adrenomyeloneuropathy Treatment Market Size by Region (2015-2026)1.4 Global Adrenomyeloneuropathy Treatment Historic Market Size by Region (2015-2020)1.5 Global Adrenomyeloneuropathy Treatment Market Size Forecast by Region (2021-2026)1.6 Key Regions Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.1 North America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.2 Europe Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.3 China Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.5 Latin America Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Adrenomyeloneuropathy Treatment Industry Impact1.7.1 How the Covid-19 is Affecting the Adrenomyeloneuropathy Treatment Industry

1.7.1.1 Adrenomyeloneuropathy Treatment Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Adrenomyeloneuropathy Treatment Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Adrenomyeloneuropathy Treatment Players to Combat Covid-19 Impact 2 Adrenomyeloneuropathy Treatment Market Overview by Therapy2.1 Global Adrenomyeloneuropathy Treatment Market Size by Therapy: 2015 VS 2020 VS 20262.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by Therapy (2015-2020)2.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by Therapy (2021-2026)2.4 Steroid Replacement Therapy2.5 Stem Cell Transplant 3 Adrenomyeloneuropathy Treatment Market Overview by Therapy3.1 Global Adrenomyeloneuropathy Treatment Market Size by End Users: 2015 VS 2020 VS 20263.2 Global Adrenomyeloneuropathy Treatment Historic Market Size by End Users (2015-2020)3.3 Global Adrenomyeloneuropathy Treatment Forecasted Market Size by End Users (2021-2026)3.4 Hospitals3.5 Clinics3.6 Ambulatory Surgical Centers3.7 Others 4 Global Adrenomyeloneuropathy Treatment Competition Analysis by Players4.1 Global Adrenomyeloneuropathy Treatment Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenomyeloneuropathy Treatment as of 2019)4.3 Date of Key Manufacturers Enter into Adrenomyeloneuropathy Treatment Market4.4 Global Top Players Adrenomyeloneuropathy Treatment Headquarters and Area Served4.5 Key Players Adrenomyeloneuropathy Treatment Product Solution and Service4.6 Competitive Status4.6.1 Adrenomyeloneuropathy Treatment Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Ascend Biopharmaceuticals5.1.1 Ascend Biopharmaceuticals Profile5.1.2 Ascend Biopharmaceuticals Main Business and Companys Total Revenue5.1.3 Ascend Biopharmaceuticals Products, Services and Solutions5.1.4 Ascend Biopharmaceuticals Revenue (US$ Million) (2015-2020)5.1.5 Ascend Biopharmaceuticals Recent Developments5.2 Novadip Biosciences5.2.1 Novadip Biosciences Profile5.2.2 Novadip Biosciences Main Business and Companys Total Revenue5.2.3 Novadip Biosciences Products, Services and Solutions5.2.4 Novadip Biosciences Revenue (US$ Million) (2015-2020)5.2.5 Novadip Biosciences Recent Developments5.3 Eureka Therapeutics5.5.1 Eureka Therapeutics Profile5.3.2 Eureka Therapeutics Main Business and Companys Total Revenue5.3.3 Eureka Therapeutics Products, Services and Solutions5.3.4 Eureka Therapeutics Revenue (US$ Million) (2015-2020)5.3.5 Human Longevity Recent Developments5.4 Human Longevity5.4.1 Human Longevity Profile5.4.2 Human Longevity Main Business and Companys Total Revenue5.4.3 Human Longevity Products, Services and Solutions5.4.4 Human Longevity Revenue (US$ Million) (2015-2020)5.4.5 Human Longevity Recent Developments5.5 Regeneus5.5.1 Regeneus Profile5.5.2 Regeneus Main Business and Companys Total Revenue5.5.3 Regeneus Products, Services and Solutions5.5.4 Regeneus Revenue (US$ Million) (2015-2020)5.5.5 Regeneus Recent Developments5.6 Allogene Therapeutics5.6.1 Allogene Therapeutics Profile5.6.2 Allogene Therapeutics Main Business and Companys Total Revenue5.6.3 Allogene Therapeutics Products, Services and Solutions5.6.4 Allogene Therapeutics Revenue (US$ Million) (2015-2020)5.6.5 Allogene Therapeutics Recent Developments5.7 BioRestorative Therapies5.7.1 BioRestorative Therapies Profile5.7.2 BioRestorative Therapies Main Business and Companys Total Revenue5.7.3 BioRestorative Therapies Products, Services and Solutions5.7.4 BioRestorative Therapies Revenue (US$ Million) (2015-2020)5.7.5 BioRestorative Therapies Recent Developments5.8 Immatics Biotechnologies5.8.1 Immatics Biotechnologies Profile5.8.2 Immatics Biotechnologies Main Business and Companys Total Revenue5.8.3 Immatics Biotechnologies Products, Services and Solutions5.8.4 Immatics Biotechnologies Revenue (US$ Million) (2015-2020)5.8.5 Immatics Biotechnologies Recent Developments5.9 NewLink Genetics5.9.1 NewLink Genetics Profile5.9.2 NewLink Genetics Main Business and Companys Total Revenue5.9.3 NewLink Genetics Products, Services and Solutions5.9.4 NewLink Genetics Revenue (US$ Million) (2015-2020)5.9.5 NewLink Genetics Recent Developments5.10 Cytori Therapeutics5.10.1 Cytori Therapeutics Profile5.10.2 Cytori Therapeutics Main Business and Companys Total Revenue5.10.3 Cytori Therapeutics Products, Services and Solutions5.10.4 Cytori Therapeutics Revenue (US$ Million) (2015-2020)5.10.5 Cytori Therapeutics Recent Developments5.11 Talaris Therapeutics5.11.1 Talaris Therapeutics Profile5.11.2 Talaris Therapeutics Main Business and Companys Total Revenue5.11.3 Talaris Therapeutics Products, Services and Solutions5.11.4 Talaris Therapeutics Revenue (US$ Million) (2015-2020)5.11.5 Talaris Therapeutics Recent Developments 6 North America Adrenomyeloneuropathy Treatment by Players and by End Users6.1 North America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)6.2 North America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 7 Europe Adrenomyeloneuropathy Treatment by Players and by End Users7.1 Europe Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)7.2 Europe Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 8 China Adrenomyeloneuropathy Treatment by Players and by End Users8.1 China Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)8.2 China Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 9 Rest of Asia Pacific Adrenomyeloneuropathy Treatment by Players and by End Users9.1 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 10 Latin America Adrenomyeloneuropathy Treatment by Players and by End Users10.1 Latin America Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)10.2 Latin America Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 11 Middle East & Africa Adrenomyeloneuropathy Treatment by Players and by End Users11.1 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Adrenomyeloneuropathy Treatment Market Size by End Users (2015-2020) 12 Adrenomyeloneuropathy Treatment Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Originally posted here:
Trending Now: Adrenomyeloneuropathy Treatment Market Brief Analysis and Application, Growth by 2026| Ascend Biopharmaceuticals, Novadip Biosciences,...

This week Dr. Greg talks with Anthony Bardo,an assistant professor with a dual appointment inHealthy Society and Populationsand theDepartment of Sociologyin theUK College of Arts and Sciences, about what a post-COVID-19 'new normal' might look like. Hebelieves its important to consider how perspectives will change. As a medical sociologist and health demographer, his research is driven by the desire to understand what contributes to quality of life across societies.

From UK Now:

From the Great Depression to the Civil Rights Movement each generation has been shaped by the national and international events that take place during their formative years.

Will the same be said for the COVID-19 pandemic?

Anthony Bardo, an assistant professor with a dual appointment inHealthy Society and Populationsand theDepartment of Sociologyin theUK College of Arts and Sciences, believes its important to consider how perspectives will change. As a medical sociologist and health demographer, his research is driven by the desire to understand what contributes to quality of life across societies.

In line with the age-old adage without your health you have nothing, scholars and politicians have recently turned to measures of health and longevity to gauge quality of life, he said. Yet, as my research has consistently shown health is only one, and not even the most important, component of quality of life.

While its difficult to predict the future, Bardos expertise and insight can help society prepare for what the world will look like months or even years from now.

And perhaps its worth considering how each generation might live their lives differently.

UKNow:The COVID-19 pandemic is changing many aspects of our lives. Can we expect some of those changes to be our new normal not just for the next few months, but years?

Bardo:Indeed, many aspects of our lives have been touched if not substantially altered.Our day-to-day behaviors, activities and routines are now shaped by mandates and policies aimed at slowing the pandemic.

Minimal Changes

Bardo:Actions tied to economic activities (e.g., shopping, work, leisure) will likely return to normal once government restrictions are lifted and community concern has diminished. However, our routines will likely continue to be shaped by a now cognizant concern for public health (e.g., hand washing, covering coughs/sneezes, isolating while sick, etc.). At first, these behaviors will likely be driven at the individual level. We may continue to see readily available sanitizing agents in public spaces, and organizations may even start to enforce sick leave policies. These circumstances beg the question, why were these fundamental functions not already ingrained in our society?

Drastic Changes

Bardo:Its apparent that improvements in quality of life are no longer closely tied to technological development. Refrigerators, washing machines, and dishwashers were certainly game changers as they allotted folks additional time for activities that were more enjoyable and/or meaningful. Yet, since the rise of the personal computer, national-level well-being has remained relatively constant.

What do we do with this new technology? We use it to purchase more things, spend more time working and less time in the physical presence of others. In a sense, weve been on a path toward social isolation for several decades by surrounding ourselves with more stuff and fewer people (at least in a physical sense).

Technological development has long been deemed the solution to enhance quality of life. It was widely thought that such advancements would ultimately lead to the good life. Now we may actually have begun recognizing that human interactions and meaningful pursuits are what we crave. Although e-commerce is at an all-time high, were not the least bit happier when packages magically appear on our doorsteps. Many are now working from home, but also yearning for some dry humor at the water cooler. Students had been begging for more online learning opportunities, but now they want nothing more than to come to campus.

Takeaway

Bardo:Im not, nor is anyone else, sure what the future holds, but if we dont take the time now to reflect on our experience, well simply continue to fall subject to the same economic forces that have made life vanillaat best.

UKNow:As unemployment persists, many are concerned about their financial future. How will COVID-19 impact career trajectories?

Bardo:A useful exercise to consider is to draw on what we now know about the long-term implications of the Great Recession and how they differ by age group.

Mid-Career (late Boomers and early Gen-Xers)

Bardo:The current pandemic has ravaged the labor market. Unlike during the Great Recession, mid-career folks may find themselves facing greater challenges compared to those on the verge of retirement. For example, the current mid-career cohort should be in their prime earning years, but they now find themselves hit with a double whammy. The Great Recession stalled their upward mobility early on. Contemporaneously, retirement and old age were reinvented in such a way to extend traditional working age (e.g., 60 is the new 50). Moreover, these shifting age norms at the latter end of the life course have major implications for younger people as well. For example, young folks increasingly find themselves in a precarious state, as adult positions and the privileges they come with continue to dwindle highlighted by a massive increase in mental health conditions such as anxiety and depression.

Relatedly, the current mid-career cohort uniquely lacks the retirement savings that previous cohorts had. This is partially due to the above noted hamper in upward mobility, but also because this mid-career cohort are grappling with increased costs of education for both themselves and their children. Many are also simultaneously supporting their adult children and aging parents, and sometimes even their grandchildren. Macroeconomic circumstances cannot, or will not, provide the same opportunities to achieve the American dream as they once did. The current pandemic only makes the future seem bleaker.

Late Boomers and early Gen-Xers have a close relationship with adversity, and they have received relatively little support along the way compared to previous cohorts. They faced numerous socioeconomic woes at critical life stages. They were children during the Oil Crisis and may have gone without during their impressionable years. They were launching their careers during the dot-com bubble, and they are much more likely to have had made career changes compared to earlier cohorts. They were finally starting to find their way during the Great Recession, and they only recently recovered to pre-Great Recession status. Given the above circumstances, its not surprising that this age group is driving the Deaths of Despair an unprecedented reversal in life expectancy because of increased mortality among whites in mid-life due to suicide and drug and alcohol abuse.

Takeaway

Bardo:In sum, the American dream certainly takes hard work and dedication, but opportunity is a prerequisite. Will opportunities abound post-pandemic? Maybe so. The more important question is, do we want the same opportunities that have provided less than an optimal quality of life?

UKNow:As teens become young adults, how might this pandemic change/shape their views on the areas below:

Higher Education

Bardo:A common strategy among young adults in response to the Great Recession was to shelter in higher education. For many this meant pursuing graduate degrees in lieu of entering the labor market after undergrad. The idea was that the recession would end, things would go back to normal and their lapse in employment would have been used to make themselves more marketable. Whether this strategy was effective remains an open question. What is clear is that the transition to adulthood has remained precarious at best, with even fewer road signs and landmarks than ever before. Moreover, the uncertainty surrounding higher education during this pandemic only adds to this dilemma what to do?

Whether to pursue higher education may seem like a relatively straightforward decision, but this decision traditionally comes at an age when timing is particularly crucial. If young adults arent in higher education making themselves more marketable (we can no longer afford to learn for the sake of learning, or maybe never have), then what will they do? Maybe they will take up low paying jobs that are now deemed essential. Or as suggested by our political leaders, they may even find something new. Regardless of what path young people choose, were likely to see another baby bust.

Family Formation

Bardo:Child rearing is a key component of family formation, and its timing in the life course has major implications for ones remaining years. Thirteen years ago, America was only coming to terms with decades-long shifts in traditional family values driven by an increase in female labor participation, two earner households and divorce rates. This is evidenced by attitude and subsequent policy shifts surrounding same-sex marriage and LGBTQ rights.

While current circumstances reflect traditional telltale signs for a baby boom (what else is there to do than Netflix and chill?), we are going to have a back-to-back baby bust (opposite of baby boom). This not only has major implications for the future trajectories of young adults themselves, but also the many institutions that were designed to serve them. Moreover, who is going to pay the taxes to support our rapidly aging population?

Social Justice

Bardo:The unique socialization of Gen-Z (the children of Gen-X) has led to increased versatility in anticipation for a bumpy road. While certainly versatile, Gen-Z is often stereotyped as being overly individualistic or even narcissistic. On the one hand, the individualistic stereotype rings true. For example, there is no cultural glue that binds this cohort together nor any that ties them to their adjacent Millennials. This is largely due to technological development and the related rise in user-generated content. On the other hand, the narcissistic stereotype couldnt be further from the truth. For example, this cohort is leading the way in terms of equality and social justice evidenced by the current protests and the Black Lives Matter movement.

Few cohorts aside from the Silent Generation have faced such levels of uncertainty during their formative years. Likely due to their formative experiences of social deprivation, Gen-Z and the Silent Generation share many characteristics. For example, the Silent Generation is often credited withforming the leadership of the Civil Rights movement. This may also be due to the circumstances of their respective parents, and the unique primary socialization they provided. The Greatest Generation enjoyed the Roaring Twenties and Gen-X soaked up the materialism of the 1980s and early '90s as young adults, and both historical periods were closely followed by turbulent times (i.e., Great Depression and Great Recession). Furthermore, both generations are characterized by a relatively high prevalence of mental health issues. Mental health was not well understood when the Silent Generation was young, but their relatively high levels of cognitive impairment likely reflects the long-term consequences of their exposure to social stressors. How might the COVID-19 pandemic impact both the immediate and long-term mental health of Gen-Z? Might the current movements come to parallel those of the Civil Rights era?

Takeaway

Bardo:Many of the issues that we face today can be linked back to the disappearing middle-class, as the social institutions that were designed to improve our lives (e.g., science, education, and medicine) have fallen under attack and those that were intended to keep us in our place (e.g., religion, marriage, and criminal justice) have simultaneously eroded. The idea of a new normal has been underway for a long time (arguably 50 years), and the current pandemic has only just thrown a wrench in these plans (e.g., What normal were we trying to achieve? Were we actually driving the train?)

UKNow:Protests across the United States are shining a spotlight on social injustice. Does COVID-19 play a role in widening social inequalities?

Bardo:We are certainly a nation divided, and the stressors of the current pandemic have heightened our awareness of our seemingly polar views. Maybe if we all took this time to come together around the common terms of our plight for the good life, we would finally recognize that we have more similarities than differences and that the only way to get there is if we stand together well, at least six feet apart for now.

More here:
Will COVID-19 Change the Way Every Generation Lives? UK Expert Offers Insight - WUKY

In June 2020, amid widespread protests against systemic police brutality and misconduct against Black Americans, elected officials and the public began to seriously reconsider the role of law enforcement in U.S. society. For years, grassroots campaigns and local advocates have called for an approach to public safety that does not rely solelyor even primarilyon the police. Now, the push from activists to shrink the role of policing and invest in social services and community-based strategies is gaining national attention.

Reducing the role of policing and the criminal justice system as a whole is not a radical concept and is based on the widely acknowledged idea that the justice system has taken on an outsize role in society. For too long, American communities have allowedand in many ways mandatedthat the criminal justice system serve as the de facto response to a broad swath of social issues, from behavioral health crises to substance misuse to school discipline. Police officers are expected to address situations that they are neither trained nor equipped to handle, which can significantly exacerbate harm for civilians. In establishing a commission on law enforcement in January 2020, even Attorney General William Barr acknowledged this point, saying, [O]ur officers must confront a wave of social problems, such as homelessness, drug addiction, and mental illness problems that demand solutions beyond their authority and expertise.

The movement to shrink the role of policing and shift public safety responsibilities to other government and community institutions has similarities to a multistate initiative to divest from prisons that has attracted significant bipartisan support. Over the past decade, 35 states have participated in the Justice Reinvestment Initiative (JRI) and signed up to reduce correctional populations and budgets and reinvest in other public safety solutions. JRI has earned praise from leaders across the ideological spectrum. Among JRIs champions are Democratic Govs. Jay Inslee of Washington and Kate Brown of Oregon, Republican Gov. Asa Hutchinson of Arkansas, and former Republican Govs. Nathan Deal of Georgia and Rick Perry of Texas.

The concept behind justice reinvestment could well be characterized as a defund prisons effort, as the model was originally rooted in the idea that the criminal justice system is too big and too costly and that communities can achieve safety by shifting resources toward other less punitive efforts. The JRI experience provides important lessons for communities seeking to redirect public safety dollars to public health and community-based models. Specifically, while JRI enabled some states to shift funding into community-building resources, a large percentage of savings were ultimately reinvested back into the criminal justice system. City policymakers must establish a sustainable infrastructure in order to implement and be held accountable for their commitments to invest in communities; otherwise, amorphous promises to fund community-based solutions can turn into funding for a different part of the criminal justice system or can easily be discarded altogether. This issue brief outlines three core components of the infrastructure that cities should establish for reinvesting in communities: a dedicated civilian office of public safety within the jurisdictions government structure; a regularized and in-depth process through which community leaders and representatives can participate in developing the jurisdictions public safety agenda and priorities; and a budgetary mechanism that gives the community direct control over the redirected investments.

The concept of justice reinvestment was first introduced in 2003 by Susan Tucker and Eric Cardora, justice system experts who were at the time affiliated with the Open Society Foundation. Although justice reinvestment was initially considered a radical proposal, the idea quickly took off. Several states piloted the justice reinvestment model into the mid-2000s, yielding significant reductions in correctional costs. Among the most notable early pilots was the Texas reinvestment initiative, which has been credited with saving more than $1.5 billion in prison construction costs and $340 million in annual operating expenditures since its enactment in 2007. Justice reinvestment in Texas earned support from leaders on both sides of the aisle, including then-Gov. Perry. [I]n 2007, with broad support from Republicans and Democrats alike, Texas fundamentally changed its course on criminal justice, he later said of the reforms, which are sometimes referred to simply as the Texas model. Taxpayers have saved billions because of our new approach to criminal justice, and theyre safer in their homes and on the streets.

By 2010, the U.S. Department of Justice (DOJ) had taken note of the models impact. That year, the DOJ teamed up with the Pew Charitable Trusts to launch JRI, a public-private partnership aimed at helping state governments implement reinvestment models. With support from the DOJ, Pew Charitable Trusts, and other JRI partners, state leaders assemble a bipartisan intergovernmental working group to analyze the drivers of incarceration and correctional spending within their jurisdictions. Based on these findings, state working groups identify and implement reform strategies aimed at reducing justice system populations and costs, with the goal of reinvesting savings into evidence-informed approaches to public safety. Through JRI, states have worked to revise mandatory minimums and other sentencing guidelines, increase parole eligibility and streamline parole processes, expand good-time and earned credits, invest in substance use treatment and problem-solving courts, and undertake other reforms aimed at reducing correctional costs and populations.

In its earliest iterations, the justice reinvestment model was envisioned as a way to shift dollars away from incarceration and into low-income communities and communities of color, the latter of which have long been unfairly targeted by the criminal justice system. Racial disparities exist at every stage in the justice system. Black Americans in particular have experienced disproportionately high rates of arrest and pretrial detention, lengthier prison sentences, and significant barriers to housing and employment upon release from incarceration. In many communities of color, overcriminalization has been paired with government disinvestment in other public institutions and community-building resources. Thus, the goal of justice reinvestment according to Tucker and Cardora was to redirect a portion of correctional spending toward rebuilding the human resources and physical infrastructurethe schools, healthcare facilities, parks, and public spacesof neighborhoods devastated by high levels of incarceration. As the model evolved, however, its emphasis on community-building dissipated. In practice, states have reinvested a large percentage of the savings realized through JRI back into their criminal justice systems. JRI states reinvested $557 million between 2010 to 2017, more than one-quarter of which went toward community supervision agencies for purposes such as hiring new probation and parole officers and expanding electronic monitoring. Correctional institutions and law enforcement agencies received a combined $123 million during this time period, most of which was used to support in-prison programming. In some jurisdictions, the savings intended for reinvestment were simply absorbed into the states general fund.

Still, some jurisdictions continue to reinvest a portion of JRI funds into community-building resources. The state of Oregon, for instance, uses JRI to fund a grant program for county-level safety initiatives, including efforts to address social service needs. Between 2017 and 2019, Oregon awarded more than $6 million to support services related to housing, education, and employment; mentoring; parental skills building; and reentry. Arkansas has used JRI to divert people with behavioral health needs away from jails and into treatment. In a 2018 op-ed for Fox News, Gov. Hutchinson wrote, The Justice Reinvestment approach allowed Arkansas to become the first state in the country to create a network of crisis stabilization units. These units provide an alternative to incarceration for individuals in crisis, for whom arrest isnt always the best option, according to Gov. Hutchinson. Now officers have a place to take someone where people are trained to recognize and treat behavioral-health issues.

Communities considering how to reimagine their public safety resources should take note of JRIs successes and shortcomings. In part, JRIs failure to reinvest in impacted communities is a symptom of its failure to meaningfully engage these communities in the first place. Although JRI has built strong coalitions of state government officials, the initiative has largely neglected to carve out a role for local leaders and members of communities most affected by the justice system. Absent community engagement, JRIs reinvestment strategy has come to reflect the priorities of state-level policymakers rather than the needs of residents. What started as an initiative to move resources into low-income communities of color has resulted instead in the reinvestment of resources into police departments, wrote Zachary Norris, executive director of the Ella Baker Center for Human Rights, in an article on JRIs shortcomings.

Sustainability is also a concern for JRI. Because policy reforms will not realize their full potential overnight, JRI requires a long-term commitment from stakeholders. According to an evaluation conducted by the Urban Institute, impatience over lack of immediate results could seriously jeopardize a states JRI effort. In other cases, state-level political turnover has threatened to derail JRI, particularly in states with term-limited legislatures. When JRIs legislative champions leave office, the future of the initiative may be put at risk. Beyond political factors, the sustainability of JRI also depends on funding. States must provide dedicated resources to implement justice system reforms, without which they will not successfully shrink correctional populations and costs.

To avoid these pitfalls, local governments should establish an infrastructure to partner with impacted communities and sustainably reshape cities public safety agendas. Such an infrastructure should include the following three components: a dedicated civilian office within the jurisdictions government; a regularized and in-depth process through which community leaders and representatives can participate in developing the jurisdictions public safety agenda and priorities; and a budgetary mechanism that gives the community direct control over the redirected investments.

City governments can help ensure that community-driven safety agendas receive the long-term political and financial support necessary to succeed by embedding nonpunitive safety solutions into the fabric of local government. Importantly, local leaders should avoid housing community-driven interventions within city agencies that have engendered distrust among residents or within public institutions that are not equipped to take on these roles. Instead, they should consider creating a new civilian-led office within the city government that is specifically designed to administer community-driven public safety priorities.

Richmond, California, provides a powerful example of the city governments role in advancing sustainable and effective community safety strategies. In 2007, Richmond launched the nations first Office of Neighborhood Safety (ONS), a civilian office focused on preventing violence and strengthening community well-being and safety. When the office was established, the city of Richmonds homicide rate was eight times higher than the national average. Ten years later, in 2017, the homicide rate had dropped by 80 percent. Unlike a police department or other traditional public safety agencies, an ONS is not part of the criminal justice system. Instead, it is intentionally housed within city government and staffed by civilians, many of whom are members of the communities most affected by the criminal justice system. This structure allows the ONS and its staff to build and maintain trust with residents who may distrust law enforcement or other justice system practitioners. Establishing a permanent office devoted to community-safety strategies can also protect against political turnover or lapses in funding, which can undermine the longevity of interventions.

As localities begin to rethink the role of policing, elected officials should empower residents to reshape the citys approach to public safety. Local elected leaders should look beyond traditional community engagement approaches, which often consist of a one-off community meeting or a survey rather than a long-term strategy for partnering with residents. These approaches often fail to capture the perspectives of residents most affected by the justice system, including low-income communities and communities of color. Survey data show that Americans who have been impacted by the justice system are significantly less likely to trust government, which in turn can deter civic participation and engagement with government officials. I feel like theyre not interested in what I have to say, explained one survey respondent from Charlotte, North Carolina. Others echoed this sentiment, expressing the belief that public officials were not answerable to their concerns.

Instead, cities seeking to create a community-driven safety agenda should create a permanent pathway for residents to both participate in policymaking and hold elected officials accountable for outcomes. One model for strengthening and systematizing the communitys role in public safety policymaking is NeighborhoodStat, an initiative operated by the New York City Mayors Office of Neighborhood Safety. NeighborhoodStat is a joint problem-solving process that empowers residents of high-crime public housing developments to partner with city agencies to craft a public safety agenda that is grounded in the communitys needs. The model was first implemented in 2016 as part of the Mayors Action Plan for Neighborhood Safety (MAP), a multiagency initiative to channel community-building resources into the 15 housing developments that accounted for a disproportionate amount of violent crime. As part of the NeighborhoodStat process, teams of resident leaders work with their neighbors to develop a set of key priorities for strengthening safety in their housing development; these priorities can range from expanding youth employment opportunities to cleaning up a local playground to installing outdoor lighting on sidewalks. Residents then meet directly with leadership from dozens of city agencies and community-based service providers to share their communitys safety priorities and delve into solutions that are responsive to their needs. During NeighborhoodStat meetings, city agencies make concrete commitments to support community-driven solutions and are held accountable for delivering on these promises in a timely fashion. Today, NeighborhoodStat is known as the operational centerpiece of MAP, which has contributed to meaningful crime reductions in public housing developments. According to recent evaluation data, serious felonies have dropped by 7.5 percent in participating housing developments, compared with only 3.8 percent in other developments.

Another key element for creating a community-driven safety agenda is ensuring that residents have an active role in guiding the citys budget priorities. Budgets are often referred to as moral documents that offer a window into a jurisdictions values and priorities. Unfortunately, city budgets tend to reflect the values and priorities of elected officials and well-organized interest groups rather than those of residents and community-based organizations. The mismatch between a citys budget and the needs of its residents can stem from a lack of community engagement in the budgeting process. Such was the case in Milwaukee, Wisconsin, where a coalition of local advocates known as the African-American Roundtable organized the LiberateMKE campaign for budget justice in 2019. When it came to Milwaukees budgeting process, There was no one in our city government that was really working to engage anyone, let alone grassroots organizations, explained MarkasaTucker, director of the African-American Roundtable and a driving force behind the launch of LiberateMKE. The campaign began with the realization that Milwaukees budget was unjust and inequitable in regards to residents needs, Tucker explained. The residents in the heart of Milwaukee were not a part of the budget.

LiberateMKEs fight for budget justice began during the summer of 2019, when the campaign askedpeopleacross Milwaukee what they wanted to see within their citys budget. The 1,100 survey responses revealed that residents favoredinvestmentsin community-based violence prevention efforts, sustainable jobs for young people, and affordable quality housing, rather than increased investments in policing. Campaign organizers hosted workshopsforresidentsto learn how to navigatethecitybudget process, equipping them with the tools to advocatefor investments that better reflected their needs.When it came time for the citys public budget hearings in October 2019, a record number of residents turned out to voice their opinions. Whereas resident attendance at budget hearings had traditionally been sparse, residents showed up in droves and gave more than 3 1/2 hours of testimony. This has probably been the most people that we have had show up to a community hearing on the budget, Milwaukee Common Council President Ashanti Hamilton commented during the hearing. According to Tucker, residents felt empowered enough to come and face the Common Council and the mayor to talk about what they wanted. The campaign ultimately convinced the Common Council to divert $900,000 from the police budget into community-driven priorities, including funding for emergency housing and summer youth employment programming. The savings were realized in part through the elimination of 60 full-time positions upon officers retirement, as well as a $300,000 reduction in the Milwaukee Police Departments vehicle replacement budget.

As the movement to rethink policing gains momentum, more and more cities are exploring ways to redirect resources away from traditional public safety approaches and reinvest in community-based safety. Shrinking the footprint of policing is a promising first step, but it must be paired with a concerted effort to build a city government that is responsive to community safety needs. Cities now have the opportunity to learn lessons from the shortcomings of the bipartisan Justice Reinvestment Initiative that has not realized its potential for reinvestment in impacted communities. To avoid the pitfalls of JRI, cities should reshape government infrastructure to foster meaningful partnerships with residents, make long-term investments in their priorities, and sustain their visions for community safety.

Ed Chung is the vice president for Criminal Justice Reform at the Center for American Progress. Betsy Pearl is an associate director for Criminal Justice Reform at the Center.

Read the original post:
How To Reinvest in Communities When Reducing the Scope of Policing - Center For American Progress

When our neurons the principalcells of the brain die, so do we.

Most neurons are created during embryonic development and have no backup after birth.Researchers have generally believed that their survival is determined nearly extrinsically, or by outside forces, such as the tissues and cells that neurons supplywith nerve cells.

A research team led by Sika Zheng, a biomedical scientist at the University of California, Riverside, has challenged this notion and reports the continuous survival of neurons is also intrinsically programmed during development.

The study, published in the journal Neuron, identifies a mechanism the researchers say is triggered at neuron birth to intrinsically decrease a general form of cell death or apoptosis specifically in neurons. When this genetic regulation is stopped, continuous neuronal survival is disrupted and leads to the death of the animal.

An organisms survival, brain function, and fitness are dependent upon the survival of its neurons. In higher organisms, neurons control breathing, feeding, sensation, motion, memory, emotion, and cognition. They can die of many unnatural causes, such as neurodegenerative diseases, injury, infection, and trauma. Neurons are long-lived cells, but the genetic controls that enable their longevity are unknown.

Zhengs team now reports the central piece of the mechanism involved is a small piece of genetic sequence in Bak1, a pro-apoptotic gene whose activation leads to apoptosis. Bak1 expression is turned off when this small piece of genetic sequence, termed microexon, is spliced in the final Bak1 gene product. Exons are sequences that make up messenger RNA.

Apoptosis is a pathway that controls cell turnover and tissue homeostasis in all metazoans, explained Zheng, an associate professor of biomedical sciences. Most non-neural cells readily engage in apoptosis in response to intrinsic and extrinsic stress. But this cellular suicidal program needs to be reined in for neurons so that they live for many years. We now show how genetic attenuation of neuronal apoptosis takes place.

Zhengs team identified the Bak1 microexon through a large-scale analysis of expression data from human tissues, mouse tissues, human developing brains, mouse developing forebrains, and mouse developing midbrains. The team first compared neural tissues with non-neural tissues in both humans and mice to identify neural-specific exons. Then, they found cortical neurons reduce their sensitivity to apoptosis as early as neuron birth. They also found apoptosis is gradually reduced during neuronal development before neurons make connections or innervate other cells, suggesting factors other than extrinsic signals can play a role.

We show neurons transform how they regulate cell death during development, Zheng said. This is to ensure neuronal longevity, which is needed to maintain the integrity of neural circuits for brain functions.

Next, Zhengs team will study whether the identified mechanism is activated in neurodegenerative diseases and injury that cause neuronal cell death.

Zheng was joined in the research by Lin Lin and Min Zhang at UCR; Peter Stoilov at West Virginia University; and Liang Chen at the University of Southern California.

This work was supported by National Institutes of Health grants MH116220, NS104041, GM137428, and EY025536.

The research paper is titled Developmental attenuation of neuronal apoptosis by neural specific splicing of Bak1 microexon.

Excerpt from:
Neurons are genetically programmed to have long lives - UC Riverside

Throughout history, longevity and eternal life have been the ultimate goal of humanity. From the king of the ancient Chinese Qin dynasty to the European alchemists during the medieval age, countless people have devoted their lives to unveil the secrets of immortality.

Although none of such efforts have been proven to grant eternal life, nowadays, modern scientists succeeded to elongate the lifespan of simple organisms, such as worms and flies, by a considerable amount with meticulous manipulation of our genes. Among many of those studies, there have been three main methods that held their significance even in the human body.

Enzyme regulation

Most notably, the Scripps Research team discovered that the disruption of enzymatic pathways by small molecules can affect the lifespan of an organism. The team used Caenorhabditis elegans, a type of a roundworm, to test their hypothesis.

According to Benjamin Cravatt, Gilula Chair of Chemical Biology at Scripps Research, C.elegans worms were used for their experiment due to their relatively short lifespans (typically lives only a few weeks). Cravatts research involved about 100 compounds that were known to inhibit serine hydrolases in mammals.

In his experiment, Cravatt used each of the 100 molecules to block the enzymatic pathway and observed their effects on the lifespan of the C.elegans. When the team treated the worms that were 1 day into adulthood with the inhibiting compounds, they found that some of the compounds extended the average lifespan of the worm by at least 15%, according to Alice Chen, a graduate student in the Cravatt lab.

Chen elaborated that among the compounds, a carbamate compound called JZL 184, even extended the lifespan by 45% when treated at the optimal dose. Through further analysis, the team concluded that JZL 184 extended the worms lifespan by inhibiting fatty acid amide hydrolase 4(FAAH-4), which is known to break down a molecule called 2-AG, a molecule linked to aging in mammals.

Whats fascinating about this finding is that monoacylglycerol lipase was not present in C.elegans worms. MAGL usually breaks down the 2-AG molecules in mammals, but in the case of Chens experiment, FAAH-4 substituted the role of MAGL.

While the findings only apply to C.elegans worms as of now, the team stated that the FAAH-4 and 2-AG pathways will suggest a new path in extending human life.

Calorie Regulation

In addition, a research team led by David Sinclair, assistant professor of pathology at HMS, found that calorie regulation extends the lifespan of yeast cells. According to Sinclair, the PNC1 protein regulates a vitamin called nicotinamide, which is an inhibitor of the Sir2 molecule. Sinclair further hypothesized that since Sir2 typically extends the lifespan of yeast cells by stabilizing the ribosomal DNA, the regulation of nicotinamide, which is its inhibitor, will consequently prolong the organisms lifespan.

While the team believed that such a regulation process was initiated by the severe calorie restriction in yeast cells, they later discovered that calorie restriction had no impact on the Sir2 level. Thus, Sinclairs team tested the effect of the molecule NAD on PNC1 levels to confirm that NAD was responsible for altering the Sir2 level. It turned out: NAD had no effect on the PNC1 level.

Undeterred, with more in-depth analysis, the team finally reached the conclusion that nicotinamide, which is one of the products of the reaction between Sir2 and NAD, was responsible for the change in Sir2 level. Based on the correlation they found between Sir2 level and nicotinamide facilitated by calorie restriction, Sinclairs team is now investigating human genes that play the same role as PNC1, according to Harvard Medical School.

Mifepristone

Finally, the research team led by John Tower, professor of biological sciences at the University of Southern California, found that the drug mifepristone extends the lives of female flies that have mated.

Before the experiment, Tower had set a premise that the sex peptide in female flies from male flies reduces the lifespan of the female flies as it causes inflammation. In his study, he and his colleagues discovered that the drug mifepristone, also called RU-486, blocked the effects of the sex peptide during reproduction, which retained the female flies health and thus extended their lifespan.

What played the most significant role in the reaction was, according to Tower, a molecule called the Juvenile hormone.

According to Towers research team, the juvenile hormone is responsible for the growth and development of fruit flies throughout their life. The sex peptide, they elaborated, boosts the effect of the juvenile hormone, which causes harmful inflammation in the flies body and enervates the male flies by shifting the metabolic pathways.

Therefore, the inhibition of the sex peptide by mifepristone also regulates the level of juvenile hormone, consequently extending the lifespan of the flies. With their further testing of the drug on C.elegans, which has similar genes as those of humans, Tower suggested that their findings may be applicable to extending the lives of humans.

The life-extending technology is still in its burgeoning stage, as it only applies to simple organisms, such as worms and flies. However, while eternal life still seems improbable, humanity will proceed one step further to unveiling the secrets of longevity with scientists perpetual efforts.

View original post here:
Opinion: The secrets behind longevity HS Insider - Los Angeles Times

Olivia de Havilland, one of the last pillars of Hollywood royalty and a contemporary of Bette Davis and Errol Flynn, died "peacefully from natural causes" Sunday at the age of 104, talent agent Jim Wilhelm told USA TODAY. Her death marks the passing of one of the last stars of classic films of the 1930s, an actress before her time in the fight for equality, and an icon who took on the studio system and won.

Best known for her sweet-natured role as Melanie Hamilton in "Gone With the Wind," the two-time Oscar winner (for 1946's "To Each His Own" and 1949's "The Heiress") will be remembered most for her beautiful diction, an air of refinement and gumption, and grace on and off camera. Outspoken and steely in real life, de Havilland starred in more than 50 films on the big and small screen from 1935 to 1988, and was known as a staunch advocate for actors rights and creative freedom in Hollywood.

Bound by the grip Warner Bros. held on her career, the 27-year-old star sued the studio in 1943, prompting a collapse of oppressive long-term contracts in Hollywood. And in the latter years of her life, the British-American actress reminded she was no pushover, making headlines by filing a lawsuit in Los Angeles over being portrayed as a gossip monger in Ryan Murphys FX show "Feud: Bette and Joan," which chronicled the longtime rivalry between actresses Davis and Joan Crawford.

She was born Olivia Mary de Havilland in 1916 in Tokyo, where her father Walter Augustus de Havilland taught English at the Imperial University and then became a patent attorney. Her mother Lilian Augusta Ruse was a stage actress educated at the Royal Academy of Dramatic Art in London, but she left her career to move to Japan with her husband.

On a family trip to California in 1919, Olivia became ill with a bronchial condition and her younger sister Joan (later to become the actress Joan Fontaine) developed pneumonia. Lilian decided to remain in California with Joan and Olivia for her daughters health. They settled in Saratoga, a suburb of San Francisco, while her father abandoned the family and returned to Japan. De Havillands mother divorced in 1925 and married George Fontaine, a strict stepfather the girls resented.

Fontaine died in 2013 at age 96. De Havilland's death was also preceded by son Benjamin Goodrich in 1991. She is survived by her daughter, Gisele Galante Chulack, son-in-law Andrew Chulack and niece Deborah Dozier Potter. Funeral arrangements will be private, Wilhelm said.

After making her Hollywood debut in a version of Shakespeare's "A Midsummer Night's Dream," de Havilland - named for the Bard's "Twelfth Night" character Olivia - made an early mark opposite Flynn. In 1934, she had signed a contract with Warner Bros., who decided to pair her with the then-unknown Australian They starred a year later in "Captain Blood," a swashbuckling hit that made the two of them bonafide stars, and they made seven more movies as one of Hollywoods most memorable on-screen romantic pairings. She played Maid Marian to Flynn's title rogue in "The Adventures of Robin Hood" in 1938, and they last appeared together in 1941s "They Died With Their Boots On."

With David O. Selznicks 1939 Civil War epic "Gone With the Wind," de Havilland said at the time that having read the Margaret Mitchell novel, she knew she could bring the character of Melanie to life, and the actress' soft voice and graceful manner made her the perfect fit for a pivotal role: Melanie's indelible goodness saved Scarlett OHara (Vivien Leigh) from social ruin more than once and even touched Scarletts hard heart. Though far less showy than Scarlett, de Havillands iconic role is deeply etched in audiences hearts.

The character earned de Havilland her first Oscar nomination, for best supporting actress, but she lost to her "Wind" co-star Hattie McDaniel. De Havilland's second nod came for 1941s "Hold Back the Dawn," where she shared the best actress category with her sister, who won for "Suspicion." De Havilland took home her own best actress Oscar five years later, for her performance in "To Each His Own," and they are still the only siblings ever to have won lead acting Academy Awards.

But de Havilland and Fontaine fostered a heated competitiveness that lasted all their lives, from childhood to stardom. That rivalry rumored to have escalated into a feud where the two didnt speak was the subject of Hollywood gossip for decades.

In 2016, three years after her sister's death, de Havilland finally broke her silence on their relationship to the Associated Press: "A feud implies continuing hostile conduct between two parties. I cannot think of a single instance wherein I initiated hostile behavior." However, she added, "I can think of many occasions where my reaction to deliberately inconsiderate behavior was defensive.

In 1949, Fontaine put it differently, telling columnist Hedda Hopper: You see, in our family, Olivia was always the breadwinner, and I the no-talent, no-future little sister not good for much more than paying her share of the rent."

De Havilland referred to her sister as Dragon Lady.

"Dragon Lady, as I eventually decided to call her, was a brilliant, multi-talented person, but with an astigmatism in her perception of people and events, which often caused her to react in an unfair and even injurious way," de Havilland said in 2016.

De Havilland, who won her second best actress Oscar for "The Heiress," was also nominated for her performance in 1948s "The Snake Pit," one of the earliest films to feature a realistic portrayal of mental illness. That role also cemented her reputation for embracing flawed and unglamorous characters.

I believed in following Bette Davis example, she told the Los Angeles Times in 1988. She didn't care whether she looked good or bad. She just wanted to play complex, interesting, fascinating parts, a variety of human experience. I wanted Melanie to be just one of the images. Let's have a few others.

Being as well-received as she was both by the public and critically for her part in "Gone With the Wind," de Havilland longed for more substantial parts early in her career, particularly more serious ones than as Flynns demure leading lady, who was usually a damsel in distress. But Warner Bros. did not support her efforts. De Havilland grew increasingly frustrated by the lack of challenging roles and began to reject scripts.

While De Havilland wanted to pursue opportunities with other studios, Warner Bros. told her they added six months more to her seven-year contract for times she had been on suspension. (Legally, studios could suspend contract players for rejecting a role, then add that time to the contract period.)

At the urging of her lawyer, she sued Warner Bros., supported by the Screen Actors Guild. The case went to the Supreme Court of California and the court ruled in her favor in 1945. Known as the de Havilland Law, the landmark decision proved to be one of the most important and far-reaching legal rulings in Hollywood, reducing the power of the studios and giving greater creative freedom to actors.

Performers of that era and later benefited from her legal case, and the law won de Havilland much respect among her peers and colleagues. Fontaine was even quoted as saying Hollywood owes Olivia a great deal. But Warner Bros. circulated a punitive letter that essentially blacklisted de Havilland. She did not work for a film studio for two years until Paramount signed her in 1946.

"As soon as my victory was legally confirmed and I was free to choose the films that I made, Paramount presented me with the script of 'To Each His Own,' " playing an unwed teenage mother. This was exactly the kind of challenge for which I fought that case," she told the AP with pride in 2016.

In addition to championing actors rights, de Havilland was known for her liberal political stance. She organized a fight for control of the Independent Citizens Committee of the Arts, Sciences and Professions, which she felt was being manipulated by a small group of Communists. She failed and then resigned, triggering a wave of resignations, including that of an actor she had recruited to the group, Ronald Reagan. Even though she had very publicly worked to organize Hollywood resistance to Soviet influence, she was called to testify before the House Un-American Activities Committee in 1958 because of her vocal liberal activism.

On the personal front, de Havilland was romantically involved with Flynn, Jimmy Stewart, director John Huston and filmmaking mogul Howard Hughes, though Havilland eventually married Navy veteran and novelist Marcus Goodrich in 1946, before divorcing in 1953. They had one son, Benjamin, who died in 1991 after a battle with Hodgkins disease.

She wed French journalist Pierre Galante in 1955, moved to Paris, and had a daughter, Gisele. De Havilland's adjustment to Parisian life was recounted in her 1962 memoir "Every Frenchman Has One." The couple divorced in 1979.

De Havilland only appeared occasionally in films in the 1950s and turned down the role of Blanche Dubois (which won Leigh her second best actress Oscar) in 1951's "A Streetcar Named Desire." While some thought it had to do with the suggestive themes of the story, she said in 2006 that she declined the part because she had recently given birth to her son.

Her few film roles in the 60s included "Lady in a Cage" (1964) and "Hush Hush Sweet Charlotte" (1964). In 1965, she was the first woman to preside on a jury for the Cannes Film Festival.

De Havilland continued acting in films until the late 1970s and on television through the 1980s. She won a Golden Globe in 1987 and also earned an Emmy nomination for "Anastasia: The Mystery of Anna." And In 2009, she lent her distinctive voice to the narration of a documentary on Alzheimers disease entitled "I Remember Better When I Paint."

In her later years, she maintained perspective on her impressive longevity: All the artists I had known during the Golden Era (live) elsewhere, she said in 2016, including the after world.

Go here to see the original:
Olivia de Havilland, Gone With the Wind actress and Hollywood royalty, dies at 104 - Mexico Ledger